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Abstract 
Idiopathic pulmonary fibrosis (IPF) is a restrictive pulmonary disorder of 
unknown aetiology with a relentless disease course and a median survival of 3 years 
after the diagnosis.  It is the most common idiopathic interstitial lung disease (ILD) 
with a basal and peripheral predominance associated with temporal and 
geographical heterogeneity.  As the pathogenesis of this disease is poorly 
understood, the aim of this work was to investigate the pathobiology of IPF in a 
prospective manner.  There is evidence of a strong association of gastro-esophageal 
reflux and vascular disease with IPF.  Moreover, a proportion of patients have 
evidence of immunological antibodies without any evidence of connective tissue or 
autoimmune disease.  The data presented in this thesis suggest that platelet-
monocyte complexes may be involved in the pathogenesis of IPF at molecular level 
as suggested by the flow cytometric data utilizing monoclonal antibodies to platelets 
(CD42a) and monocytes (CD14).  Moreover, expression of CD40L, P-selectin and 
PSGL-1 on platelets and subpopulation of leukocytes suggested that platelet 
expression of these molecules is not significantly different in IPF as compared to ILD 
other than IPF or non-ILD controls.  Furthermore, platelet mediated injury 
hypothesis is supported by significant elevation of platelet endothelial cell adhesion 
molecule in plasma of IPF patients. 
Reflux of gastric secretions into the tracheo-bronchial tree is another 
attractive hypothesis in light of remarkably high prevalence of gastro-esophageal 
reflux disease (GERD) in IPF.  The data suggest that patients with IPF have 
significantly higher gastro and extra-esophageal reflux symptoms when assessed by 
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Hull airway reflux questionnaire (HARQ).  However, there was a lack of objective 
evidence of extra-esophageal reflux measured by exhaled breath pepsin 
concentration or significantly higher prevalence of Helicobacter Pylori.  Furthermore, 
there was evidence of immune mediated injury in IPF by indirect 
immunofluorescence study of alveolar epithelial (A549) cells as significant 
membranous enhancement of A549 cells by anti-IgG antibodies was demonstrated 
in IPF patients’ sera.  However, Human umbilical vein endothelial cells (HUVEC) did 
not show any differential staining pattern with either anti-IgG or IgM.  Hence, there 
is a suggestion of alveolar epithelial disruption mediated by immune mechanisms 
with a predominant involvement of IgG antibodies.  Furthermore, epithelial 
derangement may extend into the respiratory epithelium with release of 
carcinoembryonic antigen (CEA) in peripheral circulation as evidenced by a 
significant correlation of raised CEA level and lung function impairment in IPF.   
These findings provide clinical and molecular evidence of novel mechanisms 
of pathogenesis of IPF with increased platelet-monocyte aggregation.  Moreover, 
immune mediated alveolar epithelial dysfunction involving IgG antibodies may 
provide further insight into the understanding of the pathogenesis and natural 
history of this fibrotic disease. 
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CHAPTER 1: INTRODUCTION 
1.1 PATHOGENESIS OF IDIOPATHIC PULMONARY FIBROSIS 
Idiopathic pulmonary fibrosis (IPF) is an irreversible restrictive fibrotic 
disorder of the pulmonary interstitium with a dismal prognosis.  Despite a number 
of studies evaluating the pathogenesis of this devastating disease (Chilosi et al. 
2002;Ebina et al. 2004;Erlinger et al. 1991;Gabbiani 1998;Pantelidis et al. 
2001;Selman, King, & Pardo 2001), the aetiology of IPF remains elusive.  The 
triggering factor for this parenchymal restrictive lung disease is believed to be 
alveolar epithelial injury with subsequent lung fibrosis.  The exact nature of this 
epithelial cell injury is yet to be elucidated.  This uncertainty of exact aetiology of 
this progressively fatal disease is reflected by a lack of effective disease modifying 
therapeutic agent in a series of randomised clinical trials (King, Jr. et al. 2005;King, 
Jr. et al. 2008;Raghu et al. 1991;Raghu et al. 2004;Raghu et al. 2008;Taniguchi et al. 
2010;Zisman et al. 2010).   
Historically, IPF was believed to be an inflammatory disorder but this 
hypothesis has been challenged for a number of reasons.  First, inflammation is not 
a prominent histological finding.  Second, IPF does not respond well (or at all) to 
anti-inflammatory therapy in the form of corticosteroids or other 
immunosuppressive agents.  Third, epithelial injury can lead to pulmonary fibrosis 
even in the absence of significant ongoing inflammation (Selman, King, & Pardo 
2001).  This epithelial cell injury may by immunological (either antibodies or cell 
mediated), chemical (eg, reflux of gastric contents), microbial, or particulate (organic 
or inorganic) [Figure 1.1].  
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 “Epithelial hypothesis” proposed mechanisms of alveolar epithelial injury 
and fibrosis in IPF. 
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Epithelial mesenchymal transition (EMT) is an attractive mechanism for the 
development of IPF as there is evidence to suggest that abnormal alveolar repair 
secondary to prolonged epithelial mesenchymal cell interaction (through TGF-β) 
results in pulmonary fibrosis in IPF (Sheppard 2001).  There is transformation of 
alveolar epithelial cells with loss of polarity and epithelial markers (E-cadherin and 
zonula occludens-1) to acquire spindle shape morphology and start behaving like 
mesenchymal cells with acquisition of mesenchymal markers such as alpha smooth 
muscle actin (α-SMA) (Zavadil & Bottinger 2005), vimentin, desmin and type I 
collagen.  The role of EMT in IPF is further discussed in the following section. 
Myofibroblasts: The key effector cells in pulmonary fibrosis 
Myofibroblasts are the key effector cells responsible for the production of 
extracellular matrix and expression of α-SMA (Gabbiani 1998) that contributes to 
interstitial pulmonary fibrosis.  Myofibroblasts display features of both fibroblasts 
and smooth muscle cells with contractile properties and are an essential component 
of ‘fibroblastic foci’ which are recognized as the characteristic histological feature of 
IPF.  Myofibroblasts are derived from a number of sources and have a close 
interaction with pro-coagulant signalling via thrombin [Figure 1.2].  There are three 
predominant sources of myofibroblasts.  Firstly, resident fibroblasts (Center et al. 
1993;Martin 1997) that interact with cytokines and growth factors (Sower et al. 
1995) resulting in accumulation and activation of fibroblasts.  Secondly, epithelial to 
mesenchymal transition (EMT) is a process of phenotypic change of alveolar 
epithelial cell into spindle shape morphology along with functional consequences.  
These spindle shaped cells contribute to fibroblast expansion in IPF lungs by virtue 
14 
 
of collagen deposition and extracellular matrix accumulation.  Moreover, the role of 
EMT in IPF is strengthened by microarray analysis demonstrating that many EMT 
related genes including TGF-β3 (Nawshad & Hay 2003;Romano & Runyan 2000) and 
lymphoid enhancing factor-1 (LaGamba, Nawshad, & Hay 2005) are up-regulated in 
IPF lungs.  Finally, bone marrow derived cells have recently been discovered (Bucala 
et al. 1994) and are thought to be a potential source of myofibroblasts.  These 
CD45+, Collagen 1+ and CXCR4+ cells show plasticity and traffic to the lung in 
response to a chemokine CXCL12 (Phillips et al. 2004).  However, their role in the 
pathogenesis of IPF is as yet debatable and there is paucity of robust data on the 
contribution of these subtypes of leukocytes in perpetuation and progression of 
pulmonary fibrosis in IPF.  It would be of significant importance to prospectively 
evaluate fibroblasts and myofibroblasts during the course of development of 
pulmonary fibrosis and attempt to intervene (with anti-fibrotic drugs) at a stage 
much earlier than the established honeycombing and end stage fibrosis.  Figure 1.2 
summarizes the role of myofibroblasts in the pathogenesis of IPF and its relationship 
with coagulation cascade via protease activated receptors (PAR) also known as 
thrombin receptors.  The interaction of pro-fibrotic growth factors with angiogenic 
and thrombotic mediators may be a novel mechanism in the development of 
irreversible scarring of pulmonary parenchyma in IPF. 
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Figure 1.2 Myofibroblasts, protease activated receptors and pulmonary fibrosis 
Myofibroblasts are the key component of fibrotic cascade in IPF. There is a close 
interaction between coagulation and fibrotic cascades in the pathogenesis of lung 
fibrosis. Thrombin and factor Xa are key agonists of PAR-1 receptor that leads to the 
activation of fibroblasts and differentiation into myofibroblasts and subsequent 
biological effects of profibrotic molecules resulting in lung fibrosis. These pro-fibrotic 
mediators are released by a number of cells including resident epithelial cells, 
fibroblasts and endothelial cells. PAR Protease activated receptors; EMT Epithelial-
mesenchymal transition; SMA Smooth muscle actin; TGF Transforming growth 
factor; PDGF Platelet derived growth factor; ECM Extracellular matrix. 
Resident Fibroblasts    EMT Mesenchymal progenitor cells 
 
Thrombin 
 
Factor Xa 
Pulmonary Fibrosis 
Myofibroblasts 
 
Collagen and ECM deposition 
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The gastro-esophageal reflux hypothesis 
The gastro-esophageal reflux hypothesis is attractive and intriguing as the 
histopathological analysis of IPF lung biopsies show geographical heterogeneity with 
areas of honeycomb lung interspersed with normal lung parenchyma.  It is plausible 
that recurrent episodes of gastro-esophageal reflux (including both acid and non-
acid) lead to epithelial injury in bronchocentric and bronchiolocentric distribution as 
well as part of refluxate may reach alveoli and trigger the fibrotic response.  Indeed 
there is objective evidence of a very high prevalence of classic gastro-esophageal or 
acid reflux in IPF (Raghu et al. 2006;Tobin et al. 1998).  These prospective 
randomized studies have shown a prevalence of up to 87% of patients having distal 
reflux and 63% of patients with reflux reaching proximal oesophagus.  Furthermore, 
there is recent evidence of a convincing association of gastro-esophageal reflux with 
asymmetrical IPF and acute exacerbations (Tcherakian et al. 2011).  Significant 
gastro-esophageal reflux has been documented in patients with scleroderma 
associated interstitial fibrosis, a disease with radiological and pathological 
similarities with idiopathic pulmonary fibrosis.  Moreover, Interstitial lung fibrosis is 
a major cause of death in scleroderma (Bryan et al. 1999;Ioannidis et al. 
2005;Simeon et al. 2003).  Indeed, a contributing factor to gastro-esophageal reflux 
in scleroderma is esophageal dysmotility.  The validity of “reflux” hypothesis as a 
significant cause of interstitial pulmonary fibrosis is hampered by lack of an ideal 
investigation with a high sensitivity and specificity.  The best available diagnostic 
modality for detection of GERD is ambulatory pH monitoring coupled with high 
resolution impedance manometry to detect non-acid reflux.  Gastric enzyme pepsin, 
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if detected in respiratory secretions (either BAL or exhaled breath condensate) may 
be a useful adjunct to the objective assessment of gastro and extra-esophageal 
reflux.  
As previously shown (Strugala, Dettmar, & Morice 2009), pepsin in exhaled 
breath condensate is potentially a marker of extra-esophageal reflux and it may 
have a significant contribution to epithelial injury by means of laryngopharyngeal 
reflux.  Indeed, a relationship between pulmonary aspiration and increased pepsin 
concentration in BAL has been demonstrated in animal and human studies (Farhath 
et al. 2006;Farrell et al. 2006;Metheny et al. 2004;Metheny et al. 2006;Starosta et al. 
2007;Tasker et al. 2002b;Tasker et al. 2002a;Ufberg et al. 2004;Ward et al. 2005) 
and is associated with pulmonary inflammation (McNally et al. 2011). 
It is unclear why a small proportion of population with reflux develop IPF 
when the prevalence of gastro-esophageal reflux is fairly high in general population.  
It will be interesting to explore and identify the susceptibility factors for the 
development of pulmonary fibrosis in patients with reflux.  In this regard, evaluation 
of non acid reflux may provide further insight into the pathogenesis of pulmonary 
fibrosis and its relationship with GERD. 
There has been much interest in how certain genetic differences might 
predispose to IPF.  For example, NA1/NA2 polymorphism of the IgG receptor CD16B 
is associated with IPF, supporting a role for an underlying immunological insult 
(Bournazos et al. 2010a).  Moreover, FcgammaRIIa R131H polymorphism has been 
found to be associated with the severity and progression of IPF (Bournazos et al. 
2010b).  Gene expression profiling has shown that there are clearly different gene 
18 
 
signatures in IPF patients compared to normal controls.  The genes encoding 
extracellular matrix formation and degradation are significantly increased in fibrotic 
lungs, the most distinctive being matrix metalloproteinase-7 (Zuo et al. 2002).  The 
only clearly defined genetic mutations in association with IPF are in the gene 
encoding surfactant protein C (SFTPC) and telomerase genes hTERT and TERC (Nogee 
et al. 2001;Tsakiri et al. 2007).  There is evidence of up-regulation of adenosine 2B 
receptor and prominin-1/CD133 genes in the rapidly progressive variant of 
idiopathic pulmonary fibrosis (Selman et al. 2007).  Moreover, it is possible to 
distinguish between familial and idiopathic forms of idiopathic interstitial 
pneumonias (IIP) on the basis of gene expression (Yang et al. 2007).  There is also 
evidence that shorter telomere length of circulating leukocytes increases the 
predisposition towards the development of sporadic as well as familial pulmonary 
fibrosis (Cronkhite et al. 2008).  This genetic association of IPF is interesting and 
provides a basis for further evaluation of certain genetic markers in the 
pathogenesis of this fibrotic and relentless disease of dismal prognosis.  
As there is an association of IPF with vascular disease (acute coronary 
syndrome, angina and deep vein thrombosis) even after controlling for the 
confounding factors such as age and smoking history, it is conceivable that platelets 
may be involved in the pathophysiology and are likely to have a central role in the 
alveolar epithelial/endothelial injury and fibrosis.  Indeed platelet derived serotonin  
has been linked with vascular disease and tissue fibrosis in systemic sclerosis (Dees 
et al. 2011). The vascular injury mediated by platelets does need further 
investigation. 
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1.2 PLATELET LEUKOCYTE COMPLEXES AND MARKERS OF PLATELET ACTIVATION IN 
IDIOPATHIC PULMONARY FIBROSIS 
Platelet leukocyte interaction plays a key role in inflammatory recruitment of 
these cells to combat the injurious insult [Figure 1.3].  One of the initial steps in 
inflammation and atherogenesis is the recruitment of peripheral monocytes into the 
site of vascular damage (Consigny 1995).  These platelet monocyte interactions with 
activated endothelium are mediated by a number of cell surface molecules called 
integrins and selectins.  These molecules mediate the adhesive interactions of 
peripheral monocytes with the vascular wall to withstand the local flow at the 
vascular endothelium.  Platelets do bind to peripheral blood leukocytes in diseases 
such as coronary artery disease (Furman et al. 1998), unstable atherosclerosis (van 
Zanten et al. 1994) and hypercholesterolemia (Huo et al. 2003).  In addition, 
increased platelet-monocyte binding has been observed following lung 
transplantation with a significant rise in platelet activation markers as compared to 
control patients undergoing thoracotomies (Sternberg et al. 2008).  P-selectin or 
CD62p is a 140 kDa transmembrane protein stored in alpha granules of platelets and 
Weibel-Palade bodies of endothelial cells respectively and is involved in platelet- 
neutrophil and platelet-monocyte interaction via P-selectin glycoprotein ligand-1 
(PSGL-1) on polymorphonuclear leukocytes (PMN) cell surface.  Moreover, blockage 
of PSGL-1 results in inhibition and reversal of platelet-monocyte complexes 
following platelet stimulation, suggesting a central role of PSGL-1 in platelet-
monocyte adhesion (Fernandes et al. 2003).  Activated platelets interact with PSGL-1 
on monocytes via P-selectin and monocytic MAC-1 via GPIIb/IIIa or GPIbα (Gawaz, 
Langer, & May 2005)[Figure 1.4]. 
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Figure 1.3 Platelet-Neutrophil-Monocyte interaction with endothelium. Platelets 
play a key role in PMN recruitment through PSGL-1 (CD162) and CD18 interaction 
with P-selectin (CD62p) and ICAM-2 respectively. Platelet monocyte adhesion is of 
significance in vascular disease and is mediated partially by PSGL-1. The monocyte 
adhesion with endothelium is mediated by ICAM-1 and other adhesion molecules 
including E-selectin and is one of the initial steps in atherosclerosis. There is 
increased expression of CD36 following interaction of E-selectin with monocytes. 
Moreover, PDGF is released by endothelium as well as monocytes upon activation. 
PMN Polymorphonuclear leukocytes; PSGL P-selectin glycoprotein ligand; ICAM 
Intercellular adhesion molecule; PDGF Platelet derived growth factor; vWF von 
Willibrand factor. 
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        GPIIb/IIIa           Fibrinogen      MAC-1 (CD11b/CD18) 
 
 
 
                                          
 
P-selectin                             PSGL-1 
        
 
 
 
Figure 1.4 Platelet Monocyte interaction after activation. 
The platelets in the activated state adhere with monocytes through a number of 
molecules including GPIIb/IIIa and MAC-1. Fibrinogen acts as a bridge for this 
interaction. P-selectin on platelet surface interacts with PSGL-1 on monocyte cell 
surface to form platelet monocyte complexes.  MAC-1 Macrophage-1 antigen.            
 
There is evidence of increased risk of vascular disease in idiopathic 
pulmonary fibrosis in a number of studies.  In a large cohort of 920 patients with IPF, 
an increased risk of acute coronary syndrome (odds ratio [OR], 1.53; 95% confidence 
interval CI, 1.15-2.03), angina (OR, 1.84; 95% CI, 1.48-2.29) and deep-vein 
thrombosis (OR, 1.98; 95% CI, 1.13-3.48) has been found in the period before the 
diagnosis of IPF (Hubbard et al. 2008).  Moreover, there was a significantly increased 
risk of acute coronary syndrome (RR 3.14) and deep venous thrombosis (RR 3.39) in 
the follow up period.  In another study of 630 patients for the evaluation of the 
prevalence of coronary artery disease in pulmonary fibrosis, there was a significant 
association between IPF and multi-vessel disease (OR, 4.16; 95% CI, 1.46-11.9).  
Adjustments were made for traditional risk factors and the association of coronary 
 
  
Activated platelets   Monocyte 
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artery disease was significant for non-granulomatous fibrotic lung disorders and its 
subset, idiopathic pulmonary fibrosis  (Kizer et al. 2004).   
The above findings do support the notion that pulmonary fibrosis in IPF may 
be a consequence of pro-coagulant state in the lung microenvironment.  Indeed 
there is evidence of reversal of alveolar haemostatic balance in acute lung injury as 
well as pulmonary fibrosis (Ware et al. 2006;Ware et al. 2007).  In normal 
circumstances, the lung microenvironment is antithrombotic and pro-fibrinolytic.  In 
response to injury, this equilibrium is shifted towards pro-coagulant and anti-
fibrinolytic state (Chambers 2008).  There is evidence of coagulation cascade 
activation in a number of interstitial lung diseases (ILD) (Gunther et al. 
2000;Hernandez-Rodriguez et al. 1995) including idiopathic pulmonary fibrosis 
(Imokawa et al. 1997).  Moreover, inhibition of thrombin is associated with 
attenuation of collagen deposition in bleomycin induced lung fibrosis in animal 
models (Howell et al. 2001).  This pro-coagulant environment may be accentuated as 
a result of platelet-monocyte aggregation or interaction of endothelial surface with 
activated platelets and subtypes of leukocytes.  It will be of interest to evaluate the 
possible triggers for this pro-coagulant micro-vasculature and target this aspect of 
lung pathology in the quest for a therapeutic agent in this devastating disease. 
In light of the association of idiopathic pulmonary fibrosis with vascular 
disease, we hypothesized that patients with IPF have increased tendency for 
platelet-monocyte and platelet-neutrophil interaction and form complexes, in 
particular platelet-monocyte complexes as evidenced by an investigation in patients 
with acute coronary syndrome and myocardial infarction (Sarma et al. 2002).  There 
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was evidence of significant P-selectin independent conjugation mechanism to 
platelet-monocyte adhesion seen in peripheral blood.  As platelets are key cells at 
the site of injury at microvascular compartment with other subsets of leukocytes, we 
propose that platelets are involved in the pathogenesis of this devastating lung 
disease of unknown aetiology.  The platelet-monocyte complexes may become 
clumped in the peripheral and basal lung architecture within the microvascular 
compartment and act as an initiating stimulus for alveolar epithelial injury, the 
hallmark and one of the earliest events in the pathogenesis of IPF.  It will be 
important to demonstrate a significant difference in the proportion of platelet-
monocyte complexes in a cohort of IPF patients as compared to control population.  
As there is increased thrombotic tendency not only at macroscopic level, but also at 
microvascular lung architecture level, a significantly increased platelet-monocyte 
adhesion may have a therapeutic implication, with anti-platelet agents.   
1.2.1 Platelet activation markers in pulmonary fibrosis 
CD154 or CD40 ligand (CD40L) is a type 2 membrane glycoprotein of 33 kDa 
in size, that belongs to TNF family of cytokines and is expressed by CD4+ T cells 
(Armitage et al. 1992;Noelle et al. 1992), B cells (Grammer et al. 1995), dendritic 
cells (Pinchuk et al. 1996) and platelets (Henn et al. 1998).  CD40 is the receptor for 
CD40L and is expressed by antigen presenting cells (APC) as well as fibroblasts (Fries 
et al. 1995;Sempowski et al. 1998;Sempowski, Chess, & Phipps 1997) keratinocytes 
and endothelial cells (Denfeld et al. 1996;Mach et al. 1997).  In response to CD40 
ligation, human fibroblasts release pro-inflammatory cytokines IL-6 and IL-8 
(Sempowski et al. 1998;Sempowski, Chess, & Phipps 1997) with increased 
expression of adhesion molecules ICAM-1 (intercellular adhesion molecule) and 
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VCAM-1 (Vascular cell adhesion molecule) (Yellin et al. 1995).  Fibroblast expression 
of these molecules is associated with amplification of inflammatory and repair 
processes.  There is evidence that CD40-CD40L interaction activates human lung 
fibroblasts in vitro (Cao et al. 1998;Sempowski, Chess, & Phipps 1997) and certainly 
mouse models support that this pathway plays a crucial role in lung injury in vivo.  
Furthermore, treatment with anti-CD40L antibody results in blockage of ionizing 
radiation and oxygen induced lung damage in mice (Adawi et al. 1998).  There is 
evidence of significantly increased expression of CD40L in IPF lung fibroblasts in 
comparison to non-fibrotic controls.  Moreover, blood and BAL fluid CD40L levels in 
fibrotic patients are significantly higher than controls (Kaufman, Sime, & Phipps 
2004).  These findings support the role of CD40L in the pathogenesis of lung fibrosis 
in IPF. 
CD40-CD40L interaction may be an important mechanism in human lung 
fibrosis and could be a potential target for further study in human IPF.  In view of the 
above molecular findings of CD40L in pulmonary fibrosis, the expression of this 
molecule on human platelets in patients with IPF and other interstitial lung diseases 
might provide a further insight into the molecular pathogenesis of IPF.  We 
hypothesize that this molecule is differentially expressed on platelets in peripheral 
blood of IPF patients as compared to non-IPF ILD  or patients without interstitial lung 
disease. 
CD162 or P-selectin glycoprotein ligand (PSGL)-1 is a counter receptor 
present on polymorphonuclear leukocytes and endothelial cells.  It is involved in 
neutrophil rolling on platelets by binding to P-selectin on platelets (Kuwano et al. 
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2010).  PMN rolling on platelets can be completely blocked by monoclonal 
antibodies (mAb) to one of these molecules.  There is increased monocyte binding to 
inflamed endothelium by activated platelets that is important in atherosclerosis and 
this increased adhesion of platelets with monocytes is found in patients presenting 
with acute coronary syndromes (unstable angina and acute myocardial infarction) as 
compared to patients with non-cardiac chest pain (Sarma et al. 2002).  P-selectin-
PSGL-1 interactions account for most platelet-monocyte binding and it will be 
interesting to evaluate the markers of platelet activation and platelet monocyte 
complexes in IPF as it is a disease with very close association with cardiovascular 
disease and thrombo-embolic episodes. 
1.3 ANTI-EPITHELIAL/ ENDOTHELIAL ANTIBODIES IN IPF 
As mentioned above, the triggering or inciting insult in the pathogenesis of 
IPF is believed to be alveolar epithelial injury.  The structural remodelling in IPF is 
manifested by a range of phenotypic changes in epithelial cells from cuboidal to 
squamous cells lining the alveolar walls (Carrington et al. 1978) and type II 
pneumocyte hyperplasia and metaplasia of bronchiolar epithelial cells (Katzenstein 
& Askin 1982).  There is limited data on the role of anti-epithelial antibodies in the 
aetiology and pathogenesis of this disease.  A subset of anticytokeratin antibodies 
(CK-19), that are expressed in regenerated broncho-epithelial cells, have been 
demonstrated in IPF and pulmonary fibrosis associated with collagen vascular 
disease (Fujita et al. 1999a).  Furthermore, an antibody against small airway 
epithelial cell has been demonstrated in pulmonary fibrosis associated with 
dermatomyositis (Fujita et al. 1999b).  In addition, a number of other autoantibodies 
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have been investigated in patients with pulmonary fibrosis of obscure aetiology 
(Erlinger et al. 1991;Meliconi et al. 1989;Meliconi et al. 1993;Wallace et al. 1994).  
Together, these data underscore the significance of epithelial derangement in the 
pathogenesis of pulmonary fibrosis in IPF and in association with connective tissue 
diseases where the underlying mechanisms may be immune mediated. 
The levels of circulating immune complexes are increased with deposition in 
tissues leading to complement activation in a number of chronic inflammatory 
diseases (Bodi et al. 1998;Digeon et al. 1979).  It is plausible that chronic 
inflammation of lung parenchyma precedes the interstitial pulmonary fibrosis in an 
autoimmune mechanism.  However, an inflammatory model in the pathogenesis of 
IPF has not held the promise in view of lack of effectiveness of anti-inflammatory 
therapy. 
In addition to the epithelial disintegration and associated inflammation, 
abnormal angiogenesis has been linked to the development of pulmonary fibrosis 
(Cosgrove et al. 2004).  Matrix metalloproteinases (MMPs) are involved in 
extracellular matrix remodelling, angiogenesis and wound healing.  These molecules 
are capable of degrading collagen and have been found in increased levels in BALF of 
IPF patients (McKeown et al. 2009) and this increased production is associated with 
abnormal capillary permeability.  On the basis of these observations of close 
interplay between neo-angiogenesis and increased vascular permeability, it is 
apparent that molecular abnormalities in IPF are not confined to epithelial 
derangement and endothelial-capillary basement membrane dysfunction is closely 
associated with the pathogenesis. 
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Anti-endothelial antibodies have been implicated in the pathogenesis of 
idiopathic interstitial pneumonias (IIPs) as there is evidence of increased levels of 
these antibodies in idiopathic non specific interstitial pneumonia (NSIP), the second 
commonest of the idiopathic interstitial pneumonias.  In a study of 24 patients with 
collagen vascular disease associated ILD and 20 patients with idiopathic interstitial 
pneumonias (including IPF and idiopathic NSIP), there was increased prevalence of 
anti-endothelial cell antibodies (AECA) in idiopathic NSIP and CVD-ILD (Matsui et al. 
2008).  However, there was no evidence of increased levels of these antibodies in 
IPF.  Moreover, there was no correlation between AECA and serum markers of 
interstitial lung disease namely KL-6 and SP-D.  ILD is associated with pulmonary 
endothelial cell injury as suggested by a study of 123I-MIGB kinetics (Takabatake et al. 
2005).  There was a significantly reduced washout rate of 123I-MIGB in ILD patients 
when compared to controls without interstitial lung disease suggesting endothelial 
cell injury.  Moreover, the washout rate correlated with disease severity.  A number 
of studies (Ihn et al. 2000;Orfanos et al. 2001;Wusirika et al. 2003) have suggested a 
link between anti-endothelial cell antibodies and pulmonary fibrosis in the context 
of scleroderma; a disease with radiological and pathological similarities with IPF.  
There is evidence of immune dysregulation in IPF as antiphospholipid antibodies are 
present in patients with IPF (Magro et al. 2003;Magro et al. 2006;Magro et al. 2007).  
Expression of anti-endothelial antibodies is increased in sera and lung biopsies in 
patients with IPF as compared to controls.  In addition, there is morphologic 
evidence of microvascular injury, and ultrastructural studies have demonstrated the 
changes of endothelial injury and necrosis with basement membrane collagen 
28 
 
deposition and lamellation.  These findings are suggestive of a close association of 
these antibodies with idiopathic pulmonary fibrosis and substantiate the evidence of 
their role in alveolar epithelial/endothelial injury and progression to lung fibrosis.  
1.4 CARCINOEMBRYONIC ANTIGEN AND IPF 
Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion 
and is produced during foetal development.  It was first discovered by Gold and 
Freedman in 1965 (Gold & Freedman 1965).  It is a glycosyl phosphatidyl inositol 
(GPI)-cell surface anchored glycoprotein that is crucial in metastatic dissemination of 
colonic carcinoma by acting as colon carcinoma L-selectin and E-selectin ligands.  
The production of this antigen ceases soon after birth and a very small amount is 
detectable in normal healthy individuals.  However, higher levels of CEA are present 
in smokers.  Its predominant use is as a tumour marker in serum and the most 
common tumours associated with raised CEA levels are colorectal, gastric, 
pancreatic, lung and breast.  In view of low sensitivity and specificity of this protein, 
it is not a useful screening tool in colorectal cancer.  However, it is of prognostic 
value in cases of established colorectal malignancy and the serum levels should 
return to baseline value after complete surgical resection (Goldstein & Mitchell 
2005).  Raised CEA levels have been demonstrated in IPF patients’ sera as well as 
BAL fluid, suggesting an abnormality of epithelial cell integrity associated with 
release of this tumour antigen in respiratory secretions and the vascular 
compartment. 
In this thesis, I aim to investigate the pathogenesis of idiopathic pulmonary 
fibrosis in a variety of studies ranging from gastric reflux and anti-
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epithelial/endothelial antibodies to platelet-monocyte aggregates and molecular 
markers of platelet activation.  Moreover, the association of CEA with lung function 
impairment in IPF will be explored.  It will be interesting to evaluate a number of 
hypotheses in a disease of extremely dismal prognosis without any effective 
therapeutic option and I believe that this investigation will give me an excellent 
opportunity to not only improve my understanding of IPF, but it will serve as a 
stimulus to continue further research in this field. 
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CHAPTER 2: METHODS 
This chapter presents the methods for all the studies in a systematic manner.  
The studies conducted for the investigation into the pathogenesis of IPF were 
prospective and were carried out after ethical approval was obtained by Hull and 
East Riding Research and Ethics Committee (LREC No: 08/H1304/54).  All the data 
has been kept anonymous and password protected.   
2.1 Platelet Leukocyte study 
2.1.1 Flow-cytometry  
Inclusion criteria and blood sampling 
The diagnosis of IPF was based on the ATS/ERS guidelines (Flaherty et al. 
2004).  The control subjects included patients with other ILD, including asbestosis, 
rheumatoid arthritis associated ILD and idiopathic interstitial pneumonias other than 
IPF.  The control subjects without ILD comprised healthy individuals and patients 
with COPD and other common medical conditions.  Blood from patients with IPF and 
control subjects was drawn by venepuncture via 19-gauge needle, collected into 6 
ml tubes containing 102 IU lithium heparin (BD Ltd, Plymouth, UK) and was gently 
inverted.   
Antibodies, Immunolabelling and Flow Cytometry 
Blood (50 µL) was labelled within 30 minutes of collection by incubation with 
specific antibodies for 20 minutes at room temperature.  The antibodies used for 
labelling the blood samples are shown in Table 2.1.  
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Monoclonal Antibody Fluorescent staining Molecular Marker 
1- Unlabelled Blood None None 
2- CD42a  FITC conjugated Platelets 
3- CD14  R-PE conjugated Monocytes 
4- CD62p R-PE conjugated P-selectin 
5- CD162   R-PE conjugated P selectin glycoprotein 
ligand-1 (PSGL-1) 
6- CD154  R-PE conjugated (CD40 ligand) 
7- Control  FITC control Negative Control  
8- Control  R-PE control Negative Control 
 
Table 2.1 The reagents used for labelling the peripheral blood prior to flow cytometry in 
platelet-monocyte adhesion study 
Monoclonal antibodies (mAbs) directly conjugated to fluorochromes were 
purchased from the following sources: FITC-conjugated CD42a and R-PE conjugated 
CD14; Serotec Ltd (Oxford UK).  R-PE conjugated CD62p mAb AK-4, CD162 mAb KPL-
1, CD40L (CD154) mAb MR-1 and control IgG1 were obtained from BioLegend (San 
Diego, CA, USA).   
Following volumes of mAbs were used for flow cytometry: CD42a 1µL; CD14 
1µL; CD62p 5µL; CD162 5µL; CD40L 5µL; FITC control 5 µL and R-PE control 1 µL.  
370µL of FACSLyse solution (Becton Dickinson, San Jose, CA, USA) (in 1:10 dilution 
with distilled water) was added to each sample to lyse the red blood cells.  Samples 
were run on a Becton Dickinson FACSCalibur flow cytometer, and data analysis was 
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performed using Cell Quest Pro (Becton Dickinson) software.  Samples were 
analyzed with the flow cytometer triggered on forward scatter and again by 
triggering on FL-1 to select CD42a positive platelets.  The subtypes of leukocytes 
were identified by distinct forward and side scatter properties and are shown in 
Figures 2.1 and 2.2. 
 
Figure 2.1  Flow cytometry data focusing on monocytes in red. These cells have 
similar forward scatter (FSC-H) as neutrophils but lower side scatter (SSC-H). 
 
 
Figure 2.2  Flow cytometry showing a distinct population of cells with high forward 
and side scatter identified as neutrophils (gate R1) 
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The platelet-monocyte adhesion was determined using directly conjugated 
CD14-PE and CD42a-FITC mAb.  Figures 2.3 and 2.4 shows how neutrophil and 
monocyte cut-off was used to measure platelet-monocyte complexes.  The 
percentage of platelet-monocyte binding was detected by the proportion of 
CD14High/CD42aHigh events (Upper Right quadrant) from CD42aHigh and CD42aLow 
events (Upper right and Upper Left quadrants) (Figure 2.5). 
 
 
Figure 2.3  The cut-off used to separate monocytes from platelet monocyte 
complexes (verticle line) 
 
 
Figure 2.4 The cut-off used to separate neutrophils (Left lower quadrant) by a 
horizontal line during flow cytometry where FL2 represents CD14 expression. 
CD14 
CD42a 
CD14 
CD42a 
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Figure 2.5 The platelet-monocyte complexes were measured by calculating the 
proportion of the events in upper right quadrant from the total events in both upper 
left and upper right quadrants. FL1 denotes CD42a (to mark platelets) and FL2 is 
consistent with CD14 (to mark monocytes). 
 
P-selectin, PSGL-1 and CD40L expression was measured by labelling the 
samples with CD62p, CD162 and CD154 respectively.  The samples were run at two 
settings (high and low forward scatter) to compensate for cell debris.  Moreover, 
both FITC conjugated as well as R-PE conjugated controls were used during the flow 
cytometry analysis. 
2.1.2 ELISA for P-selectin, CD40L and PECAM-1 
Plasma levels of P-selectin, CD40L and Platelet endothelial adhesion 
molecule (PECAM-1) were measured by sandwich ELISA.  All reagents were obtained 
by Bender MedSystems (Vienna, Austria).  The plasma samples were obtained by 
standard phlebotomy and kept at -80ᴼC and were thawed at room temperature 
prior to centrifuge.  A standard 96 wells ELISA plate was used for the measurement 
of the concentration of all of the above molecules.  A good quality absorbance curve 
CD14 
CD42a 
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was obtained prior to the measurements.  The plasma levels were measured in 
duplicate and the recommended manufacturer’s protocols were followed. 
2.2 Gastro-esophageal Reflux and IPF Study 
This study evaluated the role of reflux in IPF in a number of subjective and 
objective parameters.  The objective parameters included Helicobacter Pylori 
serology and exhaled breath condensate pepsin.  The subjective assessment was 
done by completing two questionnaires ie Hull airway reflux questionnaire (HARQ) 
and over-the counter-medication questionnaire. 
2.2.1 Helicobacter Pylori study 
6 ml of peripheral blood was obtained according to the standard protocol.  
The serum was stored at -80ºC immediately after centrifugation (1500xg at 20ºC for 
10 minutes).  The presence of Helicobacter Pylori was detected by rapid antibody 
detection by ELISA (immunoassay for IgG) in serum.   
2.2.2 Exhaled Breath Pepsin Study 
Exhaled breath condensate (EBC) was collected using a dreschel glass flask 
(Figure 2.6).  The participants were asked to breathe into the device while a nose 
clip was applied.  The condensate (1-2 ml) was collected after 10 minutes of tidal 
breathing.  EBC sample was divided into 250 µL aliquots.  The presence of pepsin 
was detected by lateral flow technique (by using 2 monoclonal antibodies specific to 
human pepsin).  Pepsin positivity in EBC is suggestive of extra-esophageal reflux as it 
is a gastric enzyme and respiratory secretions do not normally contain this enzyme. 
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Figure 2.6 Exhaled breath condensate device used for the collection of sample. A 
nose clip was used and 1-2 ml of sample was obtained after 10 minutes of normal 
tidal breathing. The device was kept in an ice box during the collection. 
 
2.2.3 Over-the-counter medication/Hull airway reflux questionnaire study 
As part of investigation of gastro-esophageal reflux in idiopathic pulmonary 
fibrosis, a questionnaire of over-the-counter medications was developed and was 
completed by a cohort of IPF patients and controls.  The medications included in the 
questionnaire are shown in Table 2.2. The parameters recorded in the questionnaire 
attempted to include any previous over the counter remedies and the dosage being 
taken at present and in the past. 
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Have you 
ever taken 
it? 
If YES, are 
you still 
taking it 
now? 
How many/ how 
much per day? 
For how long have you 
been taking it? (If you 
have stopped, how 
long did you take it 
for?). Please give 
approximate dates. 
Cod Liver Oil YES / NO YES / NO   
Omega 3, EPA, or 
other  fish oils 
YES / NO YES / NO   
Echinacea YES / NO YES / NO   
Garlic capsules YES / NO YES / NO   
Ginko tablets YES / NO YES / NO   
Glucosamine (with 
or without 
chondroitin) 
YES / NO YES / NO   
Guarana tablets YES / NO YES / NO   
Oil of peppermint YES / NO YES / NO   
Olbas Oil YES / NO YES / NO   
Coenzyme Q10 YES / NO YES / NO   
St John’s Wort YES / NO YES / NO   
Turmeric capsules YES / NO YES / NO   
Any others? YES / NO YES / NO   
 
Table 2.2 Over-the-counter medication questionnaire 
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For the assessment of airway reflux symptoms, Hull airway reflux questionnaire was 
completed.  It is a 14 item questionnaire with scores of 0-5 for each item (Table 2.3).   
 
Within the last MONTH, how did the following problems affect you?   
                                                                        0 = no problem and 5 = severe/frequent problem 
Hoarseness or a problem with your voice 0 1 2 3 4 5 
Clearing your throat 0 1 2 3 4 5 
The feeling of something dripping down the back 
of your nose or throat 
0 1 2 3 4 5 
Retching or vomiting when you cough 0 1 2 3 4 5 
Cough on first lying down or bending over 0 1 2 3 4 5 
Chest tightness or wheeze when coughing 0 1 2 3 4 5 
Heartburn, indigestion, stomach acid coming up (or 
do you take medications for this, if yes score 5) 
0 1 2 3 4 5 
A tickle in your throat, or a lump in your throat 0 1 2 3 4 5 
Cough with eating (during or soon after meals) 0 1 2 3 4 5 
Cough with certain foods 0 1 2 3 4 5 
Cough when you get out of bed in the morning 0 1 2 3 4 5 
Cough brought on by singing or speaking (for 
example, on the telephone) 
0 1 2 3 4 5 
Coughing more when awake rather than asleep 0 1 2 3 4 5 
A strange taste in your mouth 0 1 2 3 4 5 
 
Table 2.3 Hull airway reflux questionnaire (Courtesy of Prof Morice). This symptom 
based assessment of airway reflux has been developed to address oesophageal and 
extra-esophageal reflux symptoms (Everett & Morice 2007;Morice et al. 2011) 
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2.3 Anti-epithelial and endothelial antibodies and IPF 
Anti-epithelial antibodies 
To evaluate the role of anti-epithelial antibodies, we evaluated 56 patients 
with indirect immunofluorescence.  A549 alveolar epithelial cells were used for this 
purpose.  The cells were obtained from ECACC (animal cell line database, Wiltshire, 
UK) and were cultured in 10% serum with Dulbeco’s modified eagle medium 
(DMEM, Invitrogen, UK).  A549 cells were allowed to adhere to monospot glass 
slides, fixed with paraformaldehyde, and permeablized with 0.1% Triton X-100 for 15 
minutes.  1% PBS/BSA was used as a blocking agent and incubated for 30 minutes.  
This was followed by 30 minutes’ incubation with 1:40, 1:160 and 1:640 serum 
dilutions or with 0.1% PBS/BSA as a control.  The slides were washed by distilled 
water and air dried between each incubation.  The secondary antibodies were used 
in 1:100 dilutions and were incubated for 30 minutes.  As there was no change in 
immunofluorescence pattern with different serum dilutions, the final analyses were 
carried out with 1:40 dilution.  The secondary antibodies used in this investigation 
were bought from the following sources: 
Goat F (ab’)2 Anti-Human IgG (gamma) and Goat F (ab’)2 Anti-Human IgM (µ) 
were from Invitrogen CALTAG laboratories, Carlsbad, CA USA.  Anti-IgG and Anti-IgD 
were bought from the same source.  We commenced our study looking at IgD, IgA, 
IgM and IgG antibodies.  As the initial pilot study demonstrated no significant 
difference in immunofluorescence with IgD and IgA antibodies, we evaluated IgM 
and IgG in the detailed investigation.  Vecta Shield (Vector laboratories, CA USA) was 
used as a mounting medium.  Fluorescent antibody complexes were visualized using 
an Olympus microscope and images were recorded with a digital camera. 
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Anti-endothelial antibodies 
For the evaluation of anti-endothelial antibodies, HUVEC (Human umbilical 
vein endothelial cells) were cultured in endothelial culture medium (Invitrogen, UK).  
As they were fixed with methanol, Triton X was not used for permeabilization.  The 
serum dilution used for HUVEC was 1:40 and anti-IgG and IgM antibodies were 
incubated at 1:100 dilution.  The blocking agent used was 1%PBS/BSA and 0.1% PBS 
in BSA was used as control.  The protocol was same as for epithelial cells and anti-
IgG and IgM antibodies were from the same source as A549 cells. 
Scoring method for immunofluorescence 
Quantitative scoring for the intensity of fluorescence was performed by 
single observer (the author).  The fluorescence was scored on a scale of 0-3 for both 
IgG and IgM.  The intensity of staining was scored by taking into account the pattern 
on the whole slide rather than focusing on one particular area of abnormality.  
Following were the scores according to fluorescence on each slide: 
0= No difference in fluorescence as compared to control  
1= Mildly increased fluorescence as compared to control 
2= Moderately increased fluorescence as compared to control  
3= Severely increased fluorescence as compared to control  
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2.4 Carcinoembryonic antigen and idiopathic pulmonary fibrosis 
To evaluate the association of CEA rise with lung function impairment in IPF, we 
evaluated serum levels of CEA in a group of 43 patients with IPF.  As there is a well 
defined reference range for CEA in normal subjects (0-5 ng/ml), no healthy controls 
were evaluated in this study.  The samples were collected by standard phlebotomy 
technique using 20-gauge needle and 6 ml of whole blood was centrifuged at 1500xg 
for 10 minutes immediately after collection.  Following are the methodological 
details for each component of the study. 
(1) Measurement of serum CEA levels 
The serum level of carcinoembryonic antigen was measured by 2-site sequential 
chemiluminescent immunometric assay. 
(2) HRCT Evaluation 
Thoracic CT scans were evaluated by a single observer (the author).  The scans were 
assessed for pattern of fibrosis including predominant reticulation, predominant 
honeycombing or mixed pattern.  The extent of fibrosis was determined for the 
entire lung, using four categories (0 = no involvement, 1 = <25% involvement, 2 = 26-
50% involvement, 3 = 51-75% involvement, and 4 = 76-100% involvement).   
(3) Surgical biopsies and tissue preparation 
A lung biopsy specimen from a patient with IPF and raised CEA level (8.21 ng/ml) 
was stained for CEA.  Furthermore, normal lung tissue from a lobectomy specimen 
was used as a control in this study.  The specimens were stained using a standard 
histopathology laboratory protocol using immunohistochemistry.   
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CHAPTER 3: PLATELET MONOCYTE COMPLEXES AND IDIOPATHIC 
PULMONARY FIBROSIS 
3.1 Introduction 
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of 
unknown aetiology, characterized by irreversible pulmonary fibrosis and a restrictive 
ventilatory defect.  It is the commonest of the idiopathic interstitial pneumonias (IIP) 
with a median survival of 2.5-3 years after diagnosis (Kim, Collard, & King, Jr. 2006).  
IPF has been linked closely with cardiovascular disease (Hubbard et al. 2008) 
in observational studies and there are similarities in molecular pathogenesis of 
atherosclerosis and pathological lesions in idiopathic pulmonary fibrosis.  For 
example, monocyte recruitment to the site of vascular damage is one of the initial 
steps in atherosclerosis (Consigny 1995).  Moreover, adhesion of platelet-monocyte 
complexes to the vessel wall enhances monocyte clustering, which is mediated by P-
selectin and PSGL-1 on platelets and monocytes respectively (da Costa et al. 2004).  
In atherosclerosis, there is an exuberant endothelial fibro-proliferative response 
with recruitment of leukocytes, extracellular matrix deposition (Katsuda & Kaji 2003) 
and smooth muscle cell proliferation (Schwartz, Virmani, & Rosenfeld 2000).  IPF is 
characterized by myofibroblast stimulation and release of pro-fibrotic mediators 
culminating in an exuberant fibro-proliferative response and smooth muscle 
hypertrophy in the pulmonary vasculature in response to as yet unidentified injury.   
There is increased binding of platelets to circulating monocytes in the 
peripheral blood in patients with myocardial infarction and unstable angina (Sarma 
et al. 2002).  Moreover, there is evidence of peripheral blood monocytosis in 
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idiopathic interstitial lung diseases possibly reflecting oxidative stress associated 
with ILD (Varney et al. 2008).  This oxidative stress may be exacerbated by cigarette 
smoke.  Indeed smoking is linked with increased platelet-monocyte aggregation and 
is associated with up regulation of CD40L and its receptor CD40 (Harding et al. 
2004). 
Circulating platelet-monocyte aggregates are a sensitive marker of in vivo 
platelet activation and are superior to platelet surface P-selectin (Michelson et al. 
2001).  Platelet adhesion to monocytes and PMN leukocytes is primarily mediated 
through PSGL-1-P-selectin interaction.  This platelet interaction with leukocytes may 
alter their activation and recruitment patterns (Merhi et al. 1997;Neumann et al. 
1997;Theilmeier et al. 1999).  There is evidence of differential platelet binding to 
monocytes in comparison to PMN as the proportion of monocytes bound to 
platelets remains the same in whole blood and mononuclear cell fractions 
(Bournazos et al. 2008b).  However, PMN binding to platelets is dramatically 
reduced in isolated PMN cell preparations.  We hypothesized that there may be 
increased platelet activation in IPF leading to formation of platelet-monocyte 
complexes, which may initiate the alveolar injury at the vascular endothelial 
/alveolar epithelial interface. 
We hypothesized that there is increased platelet-monocyte adhesion in 
peripheral blood in IPF.  In this study, we used flow cytometry to examine platelet-
monocyte binding and markers of platelet activation in peripheral blood.  Moreover, 
plasma levels of P-selectin, CD40L and PECAM-1 were measured to evaluate 
correlation between these molecules and platelet-monocyte complexes. 
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3.2 Statistical analysis  
All statistical analyses were performed using SPSS (Version 17, Chicago IL, 
USA).  The Kolmogorov and Smirnov method was used to assess data distribution.  
Comparisons between patient groups were made by one-way ANOVA and 
independent sample t-tests for normally distributed data.  The data with skewed 
distributions were analysed by non-parametric tests (Mann-Whitney U test and 
Kruskal-Wallis test).  Pearson correlation coefficient was used to evaluate the 
correlation between lung function and platelet-monocyte adhesion.  A multivariate 
regression model was utilized for the comparison between markers of platelet 
activation and surface expression of these molecules on leukocytes and platelets.  
The level of statistical significance was set at 0.05. 
The power calculation analysis showed that a total of 45 subjects would 
provide 80% power to detect a difference of ≥15% in PMC at a significance level of 
5%. This calculation was conducted using estimates of effect size based on 
previously published data (Dotsenko et al. 2007).  The threshold of 15% was chosen 
on the basis of previously published data demonstrating a difference of ≥15% or 
more in patients with acute coronary syndrome and control subjects (Michelson et 
al 2001).  As there is no previous study evaluating platelet-monocyte aggregation in 
IPF, a threshold of 15% was considered biologically significant for aforementioned 
reason. 
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3.3 Results 
The basic demographics of study populations [Table 3.1] show that patients were 
older in the IPF group.  The only other significant difference in the study groups was 
in blood monocyte counts with higher counts in control patients without interstitial 
lung disease.  The rest of the parameters were similar and the groups were 
adequately matched.  The complete data with respect to diagnoses and platelet- 
monocyte binding is demonstrated in Table 3.2. 
Platelet-monocyte adhesion in Peripheral Blood 
The platelet-monocyte interaction was assessed by 2-color flow cytometry to 
distinguish monocytes and neutrophils by their distinct laser scatter properties.  
CD14 was used to identify the monocytes to eliminate the possibility of large 
lymphocytes with similar laser scatter properties to be included in the analysis.  
Platelets were identified using CD42a (FITC conjugated) and monocytes were 
identified using CD14 (R-PE conjugated).  The platelet-monocyte complexes were 
assessed by labelling the lysed blood with both CD42a and CD14. 
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Table 3.1 Selected demographics and clinical characteristics of study participants 
IPF    Non IPF ILD       Non ILD Controls       p Value 
Subjects (n)                        19     9                   14                                                           
Age (years, meanSD)          697                   589                5621                   0.005*                                                   
Gender                        0.064 
Male (n)           15   6                                 6                                                                                                     
Female (n)               4   3                     8 
 
Platelet count                24667                  24872    26591              0.882 
Monocyte count                     0.730.14                0.590.2              0.950.17              0.002* 
White cell count                      7.852.2              7.432.48                9.360.7              0.290 
Smoking (n)                     0.052 
Current    1   1          0 
Ex/ Never   18     8        14                          
Hypertension %   42  11        22              0.285 
Diabetes %     5  11        29                   0.142 
Ischemic heart disease %       5    0        11               0.642      
Thrombo-embolism %                   5  11          7               0.194 
Anticoagulation %     5  22          7                    0.215 
Clopidogrel %                 0    0          0                           
FVC % predicted                               8918               8611                            NA               0.482 
TLco % predicted                           5719               5615                       NA               0.356 
Data are presented as meanSD or percentage % unless stated otherwise. FVC: forced vital 
capacity; TLco: Total gas transfer coefficient; NA: Not applicable. 
* Statistical significance at α-level of 0.05. 
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Table 3.2 Complete data on basic characteristics, diagnoses and platelet-monocyte 
complexes (PMC) with and without EDTA. DIP: Desquamative interstitial pneumonia; FB: 
Follicular bronchiolitis; HP: Hypersensitivity pneumonitis; NSIP: Non specific interstitial 
pneumonia; RA-ILD: Rheumatoid arthritis associated interstitial lung disease. 
S.No Age Gender Diagnosis PMC (No EDTA) % PMC (EDTA) % 
1 78 M IPF 19.10 4.70 
2 62 M IPF 12.30 3.00 
3 72 M IPF 33.00 8.50 
4 68 M IPF 48.00 3.60 
5 78 F IPF 51.00 9.00 
6 83 M IPF 16.70 1.70 
7 77 M IPF 23.00 2.00 
8 73 F IPF 14.00 2.70 
9 72 M IPF 48.22 7.00 
10 75 M IPF   8.00 2.30 
11 58 M IPF 31.00 7.00 
12 61 M IPF 22.00 4.20 
13 57 M DIP 10.50 3.00 
14 51 M FB 35.30 1.00 
15 62 F RA-ILD 24.00 2.60 
16 66 F RA-ILD 18.00 3.00 
17 41 M HP 42.00 14.00 
18 56 M Occupatio
nal ILD 
NA NA 
19 31 M No ILD 32.00 2.10 
20 47 F No ILD   8.80 1.90 
21 33 F No ILD 13.00 4.70 
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S.No Age Gender Diagnosis PMC (No EDTA) % PMC (EDTA) % 
22 43 F No ILD 18.00 2.70 
23 37 F No ILD NA NA 
24 51 F No ILD   7.90 0.70 
25 82 F No ILD 17.90 3.20 
26 62 F NSIP 20.00 6.20 
27 77 M COPD 23.00 2.60 
28 51 M Crohns ILD   15.4 1.70 
29 72 F IPF 47.00 3.70 
30 69 M IPF 39.20 6.00 
31 45 M No ILD 12.60 1.20 
32 80 F IPF 65.00 12.28 
33 74 F COPD   4.01 2.80 
34 96 F No ILD 16.20 6.80 
35 65 M IPF 43.90 13.00 
36 71 M IPF 46.00 8.00 
37 79 M IPF 82.40 9.50 
38 57 M IPF   3.00 6.00 
39 79 M IHD 23.00 5.20 
40 30 M No ILD 22.00 4.00 
41 72 M Asbestosis 23.00 2.94 
42 50 M No ILD NA NA 
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The data show that there is significantly increased platelet-monocyte adhesion in IPF 
as compared to control subjects (IPF 35.6±18%, non IPF-ILD 23.5±10.4%, non-ILD 
controls 16.5±7.8%; P<0.01: one-way ANOVA; Figure 3.1).  A post-hoc analysis 
(Bonferroni) showed that the difference between platelet-monocyte binding 
between IPF and non-ILD controls was significant (P=0.004). However, the 
aggregation between IPF and non-IPF ILD failed to reach statistical significance 
(P=0.184). 
 
Figure 3.1 The proportions of mean platelet-monocyte complexes (PMC) observed in flow 
cytometry analysis showing a significantly higher percentage of platelet binding to 
monocytes in IPF group (35%) in comparison to non-ILD control subjects (16%).  
 
During this study, we evaluated the platelet-monocyte adhesion with and without 
the addition of Ethylenediaminetetraacetic acid (EDTA) to demonstrate the divalent 
cation-dependent nature of platelet-monocyte binding [Figures 3.2 and 3.3].  An 
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example of a high percentage of platelet-monocyte aggregates is depicted in Figure 
3.4. 
 
 
Figure 3.2 Platelet-monocyte complexes without EDTA show a proportion of 12% in a 
patient with IPF. 
 
 
 
Figure 3.3 Platelet-monocyte complexes with the addition of EDTA show a reduction 
in the proportion of aggregates to 3% demonstrating the cation dependent nature of 
this adhesion. 
Our findings show that there is a distinct population of CD14/CD42a-positive 
events, clearly evident in the absence of EDTA with only a small proportion of 
CD14 
CD42a 
CD14 
CD42a 
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complexes seen with the addition of EDTA (IPF 6.01% ± 3.3; non-IPF ILD 4.3% ± 4.1; 
non-ILD controls 3.1% ± 1.7) [Figure 3.5].  However, the proportion of platelet- 
monocyte adhesion in the presence of EDTA did not reach statistical significance in 
the three groups evaluated in this study (P=0.058; one way ANOVA). 
 
 
 
Figure 3.4 Platelet-monocyte binding of 65% in a patient with IPF. 
 
CD14 
CD42a 
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Figure 3.5 Platelet-monocyte complexes in three study groups with (shown in Red) 
and without EDTA (shown in Blue). There is marked reduction in platelet-monocyte 
binding following the addition of EDTA. * Statistically significant. 
 
Expression of platelet activation markers on leukocytes 
Figures 3.6 and 3.7 demonstrate the expression of PSGL-1 and CD40L on monocytes 
respectively. 
 
Figure 3.6 Monocyte expression of PSGL-1. The expression was calculated by the 
fluorescent peak on the extreme right of the graph. FL2 denotes the R-PE conjugated 
fluorescent antibody (CD162). 
 
* 
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Figure 3.7 Histogram showing an example of CD40L expression on monocytes in a 
patient with IPF. 
 
The platelet expression of activation markers was analysed at a different 
forward scatter threshold to accurately assess the surface expression of CD62p, 
CD162 and CD40L.  Figures 3.8 and 3.9 demonstrate the flow cytometric settings to 
evaluate the expression of these activation markers on platelets at a different 
forward scatter threshold. 
 
 
Figure 3.8 Platelet setting showing the events selected (circle) to evaluate the 
expression of platelet activation markers on platelets.  
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Figure 3.9 The FL-1 threshold used to select CD42a positive and negative events 
(vertical line). FL-2 denotes expression of CD62p, CD162 or CD40L. 
 
PSGL-1 and CD40L expression in different population of leukocytes 
As PSGL-1 has a key role in platelet-leukocyte-endothelial interactions and is 
constitutively expressed by all leukocytes, the expression of this molecule on 
different subsets of leukocytes (Figure 3.10) and platelets was studied during this 
investigation.  There was no differential expression of PSGL-1 on any of the 
leukocyte sub-populations (ANOVA).  
55 
 
 
Figure 3.10 PSGL-1 expression on different subsets of leukocytes in the study groups. There 
is no significant difference in the surface expression of this molecule between groups. 
 
The expression of CD40L on different subset of leukocytes is shown in Figure 
3.11. Although there was no differential expression of this glycoprotein on 
monocytes, neutrophils and lymphocytes, there was a trend towards higher CD40L 
expression on neutrophils and monocytes in non-IPF ILD as compared to IPF or non-
ILD control subjects (Kruskal-Wallis test). 
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Figure 3.11 CD40L data reflect a non-significant trend towards higher mean fluorescence on 
neutrophils and monocytes in non-IPF ILD. 
 
Platelet expression of P-Selectin, PSGL-1 and CD40L 
Similar to the data of platelet activation markers on leukocytes, the platelet 
expression of CD62p (P-selectin), CD162 (PSGL-1) and CD40L was not significantly 
different in IPF patients as compared to control subjects (Figure 3.12).   
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Figure 3.12 The platelet expression of activation markers demonstrating no differential 
expression in three study groups.  
 
Platelet-monocyte complexes and lung function parameters 
As part of the investigation of platelet-monocyte aggregates in IPF, the 
correlation between platelet-monocyte binding and lung function parameters was 
evaluated.  These data show that there was a lack of significant correlation between 
percentage platelet-monocyte binding and percent predicted FVC (P=0.150, R2=0.12) 
or percent predicted TLco (P=0.876, R2=0.01).  These correlations are demonstrated 
in Figures 3.13 and 3.14.   
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Figure 3.13 The correlation between platelet monocyte binding and percent predicted FVC 
in IPF. There was no significant correlation between these parameters (R2=0.12). 
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Figure 3.14 There was no significant correlation between platelet monocyte binding and 
total gas transfer for carbon monoxide (R2=0.01). 
 
A subgroup analysis of platelet-monocyte complexes after stratification of lung 
function (TLco<40% and ≥40%) showed no differential adhesion of platelets with 
monocytes in relation to gas transfer (P=0.88, data not shown).  These data suggest 
that platelet monocyte adhesion in independent of lung function impairment in IPF. 
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Plasma levels of CD40L (CD154), P-selectin (CD62p) and PECAM-1 (CD31) 
As part of the investigation of platelet activation markers expression in IPF, 
concentrations of CD40L and soluble P-selectin were measured in plasma.  The 
distribution of plasma levels of P-selectin and CD40L are shown in Figures 3.15 and 
3.16.   
 
 
Figure 3.15 The histogram of plasma CD62p (P-selectin) showing a normal 
distribution. Hence ANOVA was used for statistical analysis. 
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Figure 3.16 The histogram of plasma CD40L (CD154) showing a skewed distribution. 
Hence the data were analyzed by non-parametric tests. 
 
The plasma levels of P-selectin and CD40L in IPF and control subjects are shown in 
Figures 3.17 and 3.18 respectively.   
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Figure 3.17 Plasma P-selectin levels in three study groups. There was no statistically 
significant difference in plasma level in IPF or control subjects. Horizontal bars 
represent median value. 
 
The mean plasma P-selectin levels in IPF, non-IPF ILD and non-ILD control 
subjects were 22.5±6.24, 23.3±7.18 and 20.3±5.38 (ng/ml) respectively (p=0.532; 
one way ANOVA).   There was no significant difference in plasma levels of CD40L 
across three groups (p=0.621; Kruskal Wallis test).  Furthermore, there was no 
significant correlation between plasma P-selectin, CD40L and platelet monocyte 
adhesion or lung function parameters. 
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Figure 3.18 Plasma levels of CD40L (CD154) in three study groups. There was no 
statistically significant difference in the plasma level of this molecule between 
groups. 
 
As part of platelet involvement in the pathogenesis of IPF, we evaluated plasma 
levels of platelet endothelial adhesion molecule (PECAM-1).  This study population 
was slightly different than CD40L and P-selectin participants as data for PECAM-1 
was collected from two groups (IPF and non-IPF group) rather than three groups. As 
shown in Figure 3.19, plasma levels of PECAM-1 were significantly higher in IPF 
(106±37 ng/ml) as compared to control population (84±20 ng/ml)[P<0.05, unpaired 
t-test]. 
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Figure 3.19 Plasma level of Pecam-1 (ng/ml) in the study groups. There was a 
statistically significant difference in plasma level of this molecule with higher levels in 
IPF group.  
 
3.4 Discussion 
To our knowledge, this study is the first investigation of platelet-monocyte 
interaction in idiopathic pulmonary fibrosis.  Monocytes and macrophages are 
involved in the production of cytokines and tissue remodelling in many 
inflammatory disorders and indeed in atherosclerosis (Fischer-Betz, Halle, & 
Schneider 2010).  Monocytes are unique in having functional plasticity and their 
differentiation into different tissue macrophage phenotypes makes them a key 
cellular component in a number of diseases.  There is increased platelet-monocyte 
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adhesion in end stage renal disease associated with cardiovascular complications 
(Ashman et al. 2003) as well as in COPD (Maclay et al. 2011).  Moreover, there is 
evidence of progressive accumulation of monocytes in mouse atheroma, which is 
proportional to the extent of atherosclerosis (Swirski et al. 2006).  In view of the fact 
that there is increased risk of acute coronary syndrome and deep vein thrombosis 
before and after the diagnosis of IPF, it is possible that these patients are in a pro-
thrombotic state that predisposes them to have micro-emboli and subsequent 
pulmonary vascular injury.  Indeed, individuals homozygous for the pro-coagulant 
factor ˅ R506Q Leiden have increased tendency to have severe dyspnoea as well as 
decreased lung function with a restrictive ventilatory defect (Juul et al. 2005).  
Furthermore, there is evidence of activation of the clotting cascade in pulmonary 
fibrosis (Chambers & Laurent 2002).  In light of the above evidence of pro-coagulant 
environment in pulmonary fibrosis, our findings of increased platelet-monocyte 
adhesion support the findings of pro-thrombotic state in IPF.  Furthermore, these 
complexes may be the inciting source of alveolar injury culminating in fibrosis and 
irreversible scarring in IPF. 
Our findings are in accordance with a flow cytometric study in cardiovascular 
patients evaluating platelet-monocyte aggregates in patients with chest pain with 
and without myocardial infarction (Michelson et al. 2001).  Interestingly, the 
proportions of PMC in acute myocardial infarction and control patients were parallel 
to the proportions in IPF and controls respectively.  These findings further support 
the link and close association of IPF with vascular dysfunction. 
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The choice of anticoagulant can have a significant effect on the extent of 
platelet-monocyte adhesion (Bournazos et al. 2008a) as there is evidence of 
significantly reduced platelet-monocyte binding with sodium citrate compared with 
heparin or hirudin.  Hence, heparin was used as anticoagulant for this particular 
investigation. 
CD40L is a glycoprotein expressed by CD4+ T cells (Armitage et al. 
1992;Noelle et al. 1992), B cells (Grammer et al. 1995), dendritic cells (Pinchuk et al. 
1996) and platelets (Henn et al. 1998).  We did not find any significant difference in 
plasma levels of CD40L in IPF or control subjects.  It is possible that CD40L is 
differentially expressed and released in respiratory epithelium as compared to 
plasma and simultaneous measurement of this molecule in blood and BAL fluid may 
provide further insight into the interplay between this glycoprotein and platelet-
monocyte adhesion in the pathogenesis of IPF.   
As smoking may be associated with increased platelet-monocyte binding 
(Harding et al. 2004), it could be speculated that the differential platelet-monocyte 
adhesion may be confounded by smokers in IPF group.  However, there were no 
significantly different proportions of current smokers in either group to account for 
smoking associated increase in platelet-monocyte adhesion.  Hence the observed 
increase in platelet-monocyte complex formation is likely to be independent to the 
effect of nicotine in our study population. 
As platelet-monocyte adhesion has an association with cardiovascular 
disease, the finding of increased platelet-monocyte binding in IPF could be a mere 
reflection of the associated cardiovascular complications.  Hence, we evaluated the 
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prevalence of cardiovascular and thromboembolic events in the study population 
and found no significant difference in these events in either IPF or non-IPF 
population included in our study.  It suggests that the significant increase in platelet- 
monocyte complexes in idiopathic fibrosis group is independent of their 
cardiovascular risk and thrombo-embolic event profile in this cohort of participants. 
It is interesting to note that platelet-monocyte adhesion had no significant 
correlation with percent predicted FVC or TLco.  This finding of a lack of correlation 
supports the hypothesis that platelet activation is a possible cause rather than a 
consequence of pulmonary fibrosis in IPF.  It will be of interest to evaluate 
physiologic parameters of lung function impairment (including FVC and TLco) with 
platelet activation during the course of IPF to further characterize the association. 
Limitations of the study 
Although we have shown that platelet-monocyte binding is significantly 
increased in IPF and provide a possible pathologic mechanism in this relentless 
fibrotic disorder, we cannot confirm that increased monocyte adhesion to platelets 
is not a secondary event as a result of lung fibrosis and injury.  However, the finding 
of relatively lower percentages of platelet complexes with monocytes in patients 
with ILD other than IPF with a similar degree of impairment of gas exchange (data 
not shown) refutes this potential speculation.  The patients in IPF group were older 
than control subjects that may suggest that the increased platelet-monocyte 
adhesion observed in this study may be related to older age.  However a subgroup 
analysis of control subjects after stratification into younger (age <70) and older age 
groups (age >70) suggested that the platelet-monocyte binding did not differ in 
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either age group (Older group 19.810.6%, younger group 18.57%; P=0.79 
unpaired t-test).  Hence, it is unlikely that age per se would have had an effect on 
platelet-monocyte adhesion. 
Conclusion 
This study suggests that there is differential platelet-monocyte adhesion in 
idiopathic pulmonary fibrosis in comparison to control subjects without interstitial 
lung fibrosis.  Moreover, PECAM-1 is significantly elevated in plasma of IPF patients.  
The findings of this study highlight a potentially important mechanism of increased 
pro-coagulant state that may be related to increased platelet-monocyte aggregation 
in peripheral blood.  It would be crucial to evaluate the pathogenesis of this 
relentless fibrotic disorder at microvascular level for better understanding of the 
aetiology and potential therapy. 
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CHAPTER 4:  GASTRO AND EXTRA-ESOPHAGEAL REFLUX AND IPF 
4.1 Introduction 
In view of a significantly high prevalence of gastro-esophageal reflux in IPF, 
we evaluated the hypothesis that patients with IPF have higher symptom prevalence 
of acid as well as non acid reflux (assessed by the Hull airway reflux questionnaire).  
Moreover, a questionnaire was designed to address over-the-counter remedies on 
the basis of our clinical observation that patients with ILD and particularly with IPF 
take cod liver oil on a regular basis.  We enquired the frequency and dosage of the 
most common over-the-counter remedies taken by this cohort of patients and 
compared it with a cohort of COPD patients as they have similar profile of co-
morbidities. 
The objective measurement of H. Pylori prevalence was undertaken to test 
the hypothesis that there is increased prevalence of H. Pylori in IPF with subsequent 
reflux into respiratory tract resulting in alveolar epithelial injury as this bacterium is 
associated with epithelial injury of the columnar epithelium of gastric mucosa 
(Hatakeyama 2008) that may be direct injury or an immune mediated phenomenon 
(Ivie et al. 2008).   
Pepsin is an enzyme released by chief cells of the epithelial lining of gastric 
mucosa (Figure 4.1) and was discovered by Theodor Schwann in 1836.  It is released 
in pro-enzyme form pepsinogen.  In the acidic environment of stomach created by 
hydrochloric acid (HCL), pepsinogen is cleaved into its active form pepsin.  The main 
function of this enzyme is degradation of food proteins into peptides and amino 
acids.   
70 
 
Gastric enzyme pepsin and respiratory tract “Reflux hypothesis” 
 
  
                          Chief cells 
 
                      Pepsinogen 
                           HCL 
                         Pepsin 
 
                Stomach 
Figure 4.1 Pathophysiological mechanism proposed by “reflux hypothesis” as a 
potential cause of interstitial pulmonary fibrosis. Exhaled breath condensate pepsin 
may provide an additional support for objective assessment of reflux. HCL: 
Hydrochloric acid. 
 
We hypothesized that patients with IPF have episodes of gastro-esophageal 
reflux leading to alveolar epithelial injury that is repeated and might be associated 
with micro-aspiration.  There is evidence of a significant proportion of IPF patients 
having gastro-esophageal reflux disease on 24-hour oesophageal pH testing.  The 
rationale for measurement of pepsin in exhaled breath condensate is the evidence 
that this enzyme as a reliable marker of extra-esophageal reflux (Strugala, Dettmar, 
& Morice 2009). 
4.2 Statistical Analysis 
The statistical analyses were performed using SPSS (version 17, Chicago IL).  
The data with normal distribution were analysed with unpaired t-tests and skewed 
Reflux into respiratory tract 
Alveolar epithelial 
injury and fibrosis 
Parietal cell 
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data were analysed with the Mann-Whitney U test.  Categorical data were analysed 
by Pearson Chi-square and α-value of 5% was considered statistically significant. 
4.3 Results 
4.3.1 Hull Airway Reflux Questionnaire and over-the-counter medication survey 
The main demographics of study participants of the airway reflux 
questionnaire study are shown in Table 4.1.  The mean scores on reflux cough 
questionnaire were markedly higher in the IPF group as compared to the control 
subjects (IPF 19.6 ± 12.4; controls 3 ± 2.9; P<0.001) [Figure 4.2].  The upper limit of 
normal score on HARQ is 13 (for total score) with a mean of 4. 
Table 4.1 Baseline characteristics of HARQ study participants 
IPF (n=40)     CONTROL (n=50)             p Value 
 
Age                      70±12   68±15   0.210 
Gender (M/F)     31/9   31/19   0.221       
HARQ score  19.6±12.4  3.0±2.9   <0.01* 
FVC %   88±16   NA    
TLco %    56±19   NA         
Medications (n, %) 
Prednisolone  11 (27)                6 (12)   0.055 
N-acetylcysteine     3 (6)     0 (0)   0.084 
Azathioprine                   6 (15)     2 (4)   0.074 
PPI   14 (35)                5 (10)   0.004* 
Diagnoses in control group (n)                Healthy controls (40) 
COPD (6) 
Rheumatoid lung (4) 
Data are presented as meanSD unless stated otherwise. PPI: Proton pump inhibitors; 
COPD: Chronic obstructive pulmonary disease; FVC: Forced vital capacity; TLco: Total gas 
transfer for carbon monoxide; NA: Not applicable. * Statistically significant. 
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Figure 4.2 The reflux scores in IPF and control subjects. The bars show individual 
patients with height of each bar demonstrating the total score on the questionnaire 
for that participant. The data suggest a marked difference in airway reflux symptoms 
in the idiopathic fibrosis group with mean score of 19.6 as compared to 3 in control 
population. 
 
The findings of significantly worse symptom scores on the questionnaire do 
support the hypothesis that GERD might play a significant role in the pathogenesis of 
idiopathic pulmonary fibrosis.  The over the counter survey was undertaken in 152 
adults with a larger cohort of patients with COPD (n=100) and other interstitial lung 
diseases to compare the intake of over the counter medications with IPF population.  
The data show that there was no significant difference in the intake of these 
remedies over time in either group studied during this survey (Table 4.2; Pearson 
Chi-square). 
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Table 4.2 Over-the-counter medications survey 
 
Diagnosis                                      Cod Liver Oil/Omega 3                    No OTC Mediciation 
          
IPF (n=34)   19 (56%)                11 (32%) 
 
Other ILD (n=18)   11 (61%)     6 (33%) 
 
COPD (n=100)   49 (49%)   35 (35%) 
                       P=0.569 
The data are presented as number and percentages. The data were divided into two groups 
after evaluation of a whole range of remedies as there were a very small number of 
participants taking remedies other than Cod liver oil/Omega 3 capsules. OTC: over-the- 
counter. 
 
4.3.2 Helicobacter Pylori study 
A total of 57 patients were included in the study.  The main demographics of the 
study population are shown in Table 4.3.  The main findings of the serology are 
shown in Table 4.4.  There was no significant difference in the proportion of patients 
with IPF and controls in terms of H. Pylori infection (P=0.419 Pearson Chi-square).  
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Table 4.3 Baseline characteristics of Helicobacter Pylori Study participants* 
         IPF (n=34)                  CONTROL (n=23)                       p Value 
 
Age                       71±10   67±13   0.032* 
Gender (M/F)      29/5   9/14   0.001* 
FVC %    81±21   81±23   0.988 
TLco %     44±20   64±28                 0.212 
Medications (n, %) 
Prednisolone   11 (32)   6 (26)   0.419 
N-acetylcysteine      1 (3)     0 (0)   0.596 
Azathioprine                    5 (17)   3 (13)   0.590 
PPI          15 (44)                 6 (26)   0.047* 
Diagnoses in control group (n)    COPD (8) 
Rheumatoid lung (5) 
Sarcoidosis (2) 
Respiratory infection (4) 
Miscellaneous (4)               
Data are presented as meanSD unless stated otherwise. * Statistically significant. 
 
Table 4.4 Cross-tabulation of H. Pylori status against the diagnosis    
  H. Pylori status 
Diagnosis                                        Positive                    Negative       Total  
         
IPF      17              17         34 
 
Control    14               9         23 
 
Total    31             26         57  
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   H. Pylori positivity in relation to proton pump inhibitor intake is shown in Table 4.5. 
   Table 4.5 Subgroup analysis of H. Pylori positivity and PPI usage.  
 
   PPI usage   
Diagnosis   Yes No Total 
 H Pylori  Positive 7 10 17 
IPF  Negative 8 9 17 
 Total  15 19 34 
Controls H Pylori Positive 2 12 14 
  Negative 4 5 9 
 Total  6 17 23 
                P=0.212 
4.3.3 Exhaled Breath Condensate Study 
The main demographics of the study population are shown in Table 4.6. The analysis 
of EBC pepsin showed that there was no significant difference in pepsin positivity 
between IPF and control patients (IPF 2/17, controls 0/6; P=0.379; Chi square). 
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Table 4.6 Baseline characteristics of Exhaled Breath Condensate study participants 
            IPF (n=17)        CONTROL (n=6)                    p Value 
 
Age                       72±7   52±15   0.004* 
Gender, n (M/F)     10/7   4/2   0.717      
FVC %     86.2±18.8  97.6±20  0.932  
TLco %     63.2±19.5  62±17   0.520 
Medications (n, %) 
Prednisolone   3 (17)                 1 (17)   0.730 
N-acetylcysteine    1 (6)      0 (0)   0.739 
Azathioprine                  2 (12)      0 (0)   0.538 
PPI          6 (35)    1 (17)   0.382     
Pepsin positivity (n, %)     2 (12)      0 (0)   0.379 
Data are presented as meanSD unless stated otherwise. * Statistically significant. 
 
4.4 Discussion 
The present study of investigation of gastro-esophageal and extra-
esophageal reflux in idiopathic pulmonary fibrosis has shown significantly increased 
airway reflux symptoms in IPF population.  However, there is no objective evidence 
of significant difference in H. Pylori infection or extra-esophageal reflux detected by 
exhaled breath pepsin analysis.  The association of GERD and interstitial pulmonary 
fibrosis of obscure aetiology has been documented long before the term IPF was 
even described (Belcher 1949).  More recently, Tobin and colleagues (Tobin et al. 
1998) investigated 17 patients with biopsy proven IPF and 8 control patients with 
other interstitial lung diseases in a prospective study.  There were significantly 
higher proportions of IPF patients (16 out of 17) who had abnormal distal and/or 
proximal oesophageal acid exposure as compared to controls (4 out of 8).  Raghu 
and colleagues (Raghu et al. 2006) evaluated 46 IPF patients and 133 intractable 
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asthmatics with 24-hr pH testing.  There was a significantly increased prevalence of 
abnormal acid exposure in IPF group (87% Vs 68%, P=0.014).  Moreover, the odds of 
having IPF in patients with abnormal acid exposure were 3.19 (OR).  These studies 
suggest that gastro-esophageal reflux is very common on objective measurements in 
IPF.  However, classic GERD symptoms are not observed in the majority and were 
only seen in 25 - 47% of IPF patients.  
HARQ data show a marked difference in reflux scores between IPF and 
control subjects in our study.  Hull airway reflux questionnaire is designed to pick up 
non-acid airway reflux (laryngo-pharyngeal reflux) that can be brief and occur at 
repeated intervals and looks at these symptoms in the last four weeks.  This 
symptom based assessment provides a comprehensive evaluation of both acid and 
non acid reflux episodes. The rationale of investigating these symptoms in the 
evaluation of reflux is based on a clinical study of gastro-esophageal reflux (Everett 
& Morice 2007) and is part of standard evaluation in every patient presenting with 
chronic cough at our institution. 
The exhaled breath pepsin measurement was taken in outpatient clinic 
(single measurement for each patient) whereas the episodes of reflux over a period 
of 24 hours indicated by Hull airway reflux questionnaire may have been occurring 
infrequently and we possibly missed them.  Moreover, the addition of 0.01M citric 
acid prior to collection of EBC may improve the diagnostic yield as it stabilizes the pH 
of EBC sample. 
The prevalence of H. Pylori infection varies with geographical location and 
the laboratory method to identify the infection.  In an Australian study (Moujaber et 
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al. 2008), a prevalence of 15% has been reported, while a study of Italian villagers 
showed the prevalence to be as high as 58% (Zagari et al. 2008).   
In our study, there were significantly higher proportions of patients taking 
proton pump inhibitors (PPI) in IPF group as compared to controls (44% Vs 26% 
respectively).  However, a subgroup analysis showed that being on PPI did not have 
a significant effect on H. Pylori positivity.  Hence, it is unlikely that patients’ 
exclusion on the basis of PPI usage would have had an effect on Helicobacter status.  
Moreover, H. Pylori infection can itself be associated with achlorhydria with a 
reduction in acid reflux and could potentially be an explanation for failure to find a 
difference in H. Pylori status in IPF and control subjects.  Secondly, the relatively 
lower sensitivity of H. Pylori serology to detect present infection in comparison to 
faecal stool antigen test may be another factor.  The finding of a significantly 
increased prevalence of both acid and non-acid reflux symptoms in the study 
population is interesting and is in contrast to the studies of gastro-esophageal reflux 
and IPF.  It may be the result of inclusion of a comprehensive evaluation of reflux 
symptoms by HARQ in contrast to only addressing the typical heartburn/acid reflux 
symptoms in previous studies (Bandeira et al. 2009;Raghu et al. 2006;Tobin et al. 
1998). 
We lack a gold standard test to objectively assess the gastro and extra-
esophageal reflux and it will be important to utilize novel techniques of airway reflux 
assessment, such as pharyngeal pH testing by a minimally invasive probe.  This 
newer technique, which detects liquid as well as aerosolized acid, is inserted 
transnasally and rests just behind the soft palate for between 24 and 48 hours and 
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the data is transmitted by wireless telemetry to a recorder (Restech Dx-pH 
measurement system, Respiratory Technology Corporation, San Diego, California, 
USA).  It has detected upper airway reflux in a series of patients in whom 24-hr 
oesophageal pH testing failed to detect any significant gastro-esophageal acid reflux 
(Molyneux, Morice, & Jackson 2010). 
Conclusion 
This study of investigation of gastro and extra-esophageal reflux in IPF 
demonstrates that IPF patients have a high prevalence of airway reflux symptoms.  
However, H. Pylori infection or single exhaled breath pepsin analysis is not helpful in 
the diagnosis of gastro-esophageal reflux.  As the measurement of exhaled breath 
pepsin is dependent on the timing of reflux symptoms, repeated sampling with a 
portable device immediately after the symptoms of reflux may increase the 
diagnostic yield.  A larger prospective study to evaluate the contribution of reflux, by 
both detailed subjective and objective measurements including airway pH analysis 
might be able to address the association in greater detail.  
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CHAPTER 5:  ANTI-EPITHELIAL AND ENDOTHELIAL ANTIBODIES AND 
PULMONARY FIBROSIS  
5.1 Introduction 
This indirect immunofluorescence study evaluated the role of anti-epithelial 
and endothelial antibodies in the pathogenesis of IPF.  A549 (alveolar epithelial cells 
of an adenocarcinoma lung cancer line) and HUVEC (Human umbilical vein 
endothelial cells) were used to evaluate anti-epithelial and anti-endothelial 
antibodies respectively.  The aim of this investigation was to evaluate if there is any 
evidence of a significant difference in membranous, cytoplasmic, nuclear or mixed 
fluorescent staining in IPF, non-IPF ILD and non-ILD control subjects. 
IPF or control patients’ sera in 1:40 dilution were followed by incubation with 
FITC conjugated anti-IgG or anti-IgM to detect antibody binding to either alveolar 
epithelial or endothelial cells.  An example of membranous staining with A549 cells 
is shown in Figure 5.1.  Cytoplasmic staining pattern is depicted in Figure 5.2. The 
intensity of magnification is shown in bottom right corner of the slides. 
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Figure 5.1 Membranous staining of A549 (alveolar epithelial) cells with FITC 
conjugated anti-IgG antibody. 
 
Figure 5.2 An example of cytoplasmic and membranous staining with anti-IgG 
antibody. There is a relative lack of nuclear staining in majority of cells. 
X 40 
X 40 
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5.2 Statistical analysis 
As the data in this study was categorical according to the grading of 
immunofluorescence staining, the Chi-square test was used to compare the intensity 
of fluorescence staining in the study groups.  A General Linear Model (univariate) 
was used to evaluate the relationship of the severity of immunofluorescence and 
lung function impairment measured by percent predicted forced vital capacity (FVC) 
and carbon monoxide gas transfer (TLco). 
5.3 Results 
We used FITC conjugated anti-IgM and anti-IgG antibodies in this study to detect 
binding of immunoglobulins in patients’ sera to A549 or HUVEC.  There was no 
significant difference in the staining pattern at serum dilutions of 1:40, 1:160 and 
1:640 during the pilot study (Figures 5.3-5.5).  Hence, the subsequent analyses were 
carried out using 1:40 dilution.  
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Figure 5.3 An example of immunofluorescence pattern in a membranous distribution 
in A549 cells incubated with serum (1:40) from an IPF patient, followed by FITC 
conjugated anti-IgG antibody. 
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Figure 5.4 The serum sample diluted at 1:160 without significant change in the 
fluorescence intensity. 
 
X 40 
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Figure 5.5 The sample as shown in figures 5.3 and 5.4 at a serum dilution of 1:640. 
There has been no significant difference at three different levels of serum dilution. 
 
Immunofluorescence staining on alveolar epithelial (A549) cells 
The baseline characteristics and demographics of study population are shown in 
Table 5.1. The diagnoses in control groups are shown in Table 5.2.  The data show 
that there was significantly increased immunofluorescence with serum IgG 
antibodies in idiopathic pulmonary fibrosis as compared to interstitial lung diseases 
other than IPF and control subjects without ILD (Table 5.3, P=0.03; Pearson Chi-
square).  Examples of differential fluorescence of IPF patients’ sera in comparison to 
control serum IgG and IgM on alveolar epithelial cells are shown in Figures 5.6-5.20.  
The pattern of immunofluorescence was membranous in the majority of samples.  
X 40 
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However, one patient had evidence of conspicuous nuclear staining (Figure 5.16).  
There was no statistically significant difference in immunofluorescence with serum 
IgM antibodies (P=0.349; Chi-square).   
 
 Table 5.1 Selected demographics of participants in anti-epithelial antibody study 
IPF    Non IPF ILD       Non ILD Controls       P Value 
Subjects (n)                      28     9                  19                                                           
Age (years, meanSD)          728.4                  6510                6712                      0.087 
Gender           0.045* 
Male (n)           22    4                              9                                                                                                    
Female (n)             6    5                   10 
IgG (g/L)    147  142   94  0.334 
IgM (g/L)   0.70.3                 1.20.3               0.92.0.2                 0.286 
IgA (g/L)    3.52.1  3.82.3   2.91.5  0.852 
FEV1%    8814  8124     7429  0.386 
FVC%    8416  7121    919.0  0.290 
TLco%    5820  4510  8014.7  0.083 
Data are presented as meanSD unless otherwise stated. * Statistically significant 
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Table 5.2 The diagnoses in control subjects 
Non IPF interstitial lung diseases              (n=9) 
Cryptogenic organizing pneumonia   n=2 
Non specific interstitial pneumonia n=2 
Hypersensitivity pneumonitis n=1 
Radiation pneumonitis n=1 
Rheumatoid lung n=1 
Amiodarone lung n=1 
Sjogren’s syndrome n=1 
Non ILD control subjects           (n=19) 
Chronic obstructive pulmonary disease n=12 
Healthy controls n=4 
Lower respiratory tract infection n=1 
Asthma n=1 
Congestive cardiac failure n=1 
 
 
Table 5.3 Staining of A549 cells with anti-IgG in IPF and control subjects 
   Diagnoses           Grading of immunofluorescence staining 
      0          1      2        3                               Total 
 IPF (n)     1        13   6        8          28 
 Non IPF ILD (n)    1         4  0        4               9 
 Non ILD Controls (n) 10         7  1        1        19 
 Total   12        24   7        13          56 
 P=0.034 Chi-square  
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Figure 5.6 An example of PBS control without serum followed by FITC conjugated 
anti-IgG demonstrating minimal fluorescence on A549 cells. 
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Figure 5.7 An example of PBS control without serum followed by FITC conjugated 
anti-IgM demonstrating minimal fluorescence on A549 cells. 
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Figure 5.8 Immunofluorescence in a membranous and cytoplasmic pattern following 
incubation with FITC conjugated anti-IgG in a patient with IPF. It was scored 2 on 
fluorescence severity grade. 
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Figure 5.9 Anti-IgG antibodies in another IPF patient demonstrating a remarkably 
striking immunofluorescence in a membranous pattern. This was scored 3 on the 
fluorescence severity grade. 
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Figure 5.10 Alveolar epithelial cells incubated with serum from an IPF patient 
followed by FITC conjugated anti-IgG antibody demonstrating immunofluorescence 
in a membranous pattern. 
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Figure 5.11 Another example of anti-IgG antibodies in an IPF patient demonstrating 
immunofluorescence in a membranous pattern. 
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Figure 5.12 FITC conjugated anti-IgG in a control patient with COPD demonstrating 
cytoplasmic staining. 
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Figure 5.13 A549 cells incubated with serum from a control subject without 
interstitial lung disease, followed by FITC conjugated anti-IgM antibody. There is no 
significant fluorescence staining. 
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Figure 5.14 Another example of anti-IgM antibodies on alveolar epithelial cells 
(A549) demonstrating mild fluorescence in a membranous pattern in a control 
patient with COPD.  
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Figure 5.15 Anti-IgG antibodies with a very strong staining on alveolar epithelial cells 
(A549) demonstrating a very prominent fluorescence in a membranous pattern in a 
patient with IPF.  
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Figure 5.16 A549 cells incubated with serum from an IPF patient, followed by FITC 
conjugated anti-IgG antibody demonstrating prominent nuclear immunofluorescence 
staining pattern. 
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Figure 5.17 FITC conjugated anti-IgG antibodies in a patient with Sjogren’s 
associated interstitial pulmonary fibrosis demonstrating focal membranous 
fluorescence. 
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Figure 5.18 Anti-IgG antibodies in a patient with IPF with minimal fluorescence on 
alveolar epithelial cells. 
 
 
 
 
 
 
X 60 
101 
 
 
 
 
 
 
Figure 5.19 Anti-IgM antibodies on alveolar epithelial cells demonstrating minimal 
membranous fluorescence in a non-ILD control patient with COPD.  
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Figure 5.20 Anti-IgM antibodies on alveolar epithelial cells demonstrating 
membranous fluorescence in a non-ILD control patient with COPD. 
 
 
Immunofluorescence staining on Human umbilical vein endothelial cells 
The baseline characteristics and demographics of study population are shown in 
Table 5.4. In contrast to A549 cells, HUVEC failed to show a differential pattern of 
fluorescence in IPF and control groups both in terms of IgG (Table 5.5; P=0.165 
Pearson Chi-square) and IgM antibodies (Table 5.6; P=0.297 Pearson Chi-square). 
Examples of FITC conjugated anti-IgG and IgM on HUVEC in IPF and control patients’ 
sera are shown in Figures 5.21-5.33.   
 
X 60 
103 
 
Table 5.4 Selected demographics of participants in anti-endothelial antibody study  
IPF    Non IPF ILD       Non ILD Controls       P Value 
Subjects (n)                      12     3                  13                                                           
Age (years, meanSD)          7310                  628                6911                     0.292                                                   
Gender           0.542 
Male (n)           9    2                              7                                                                                                    
Female (n)             3    1                   6 
FVC%    8316 (n=10) 877(n=2) NA                 0.569 
TLCO%    5120 (n=10)       7516 (n=6) NA  0.340 
Data are presented as meanSD unless stated otherwise. 
 
Table 5.5 Staining of anti-IgG (HUVEC) in IPF and control subjects 
   Diagnoses     Immunofluorescence staining 
        0        1      2        3                  Total 
   IPF (n)     3        2   3        4      12 
   Non IPF ILD (n)    1        1  1        0        3 
   Non ILD Controls (n)   3        8  2        0       13 
   Total      7      11              6        4       28 
 P=0.165 Chi-square  
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   Table 5.6 Staining of anti-IgM (HUVEC) in IPF and control subjects 
   Diagnoses     Immunofluorescence staining 
        0         1      2        3                Total 
   IPF (n)     5         4   2        1       12 
   Non IPF ILD (n)    3         0  0        0         3 
   Non ILD Controls (n) 11         1  1        0       13 
   Total    19         5      3        1       28 
    P=0.297 Chi-square 
 
Figure 5.21 An example of PBS control without serum with minimal fluorescence on 
endothelial cells following incubation with FITC conjugated anti-IgG antibody. 
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Figure 5.22 An example of PBS control without serum with minimal fluorescence on 
endothelial cells following incubation with FITC conjugated anti-IgM antibody. 
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Figure 5.23 FITC conjugated anti-IgM antibodies in a control patient without ILD 
demonstrating minimal fluorescence on HUVEC. 
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Figure 5.24 HUVEC incubated with serum from a patient with Rheumatoid associated 
ILD, followed by FITC conjugated anti-IgG antibody demonstrating no significantly 
increased immunofluorescence. 
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Figure 5.25 HUVEC incubated with serum from a patient with IPF, followed by FITC 
conjugated anti-IgM antibodies showing no significant immunofluorescence.  
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Figure 5.26 Endothelial cells incubated with serum from an IPF patient, followed by 
anti-IgG antibody. There is minimal fluorescence.  
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Figure 5.27 Anti-IgG antibodies in a control patient with COPD demonstrating mild 
immunofluorescence on HUVEC in a membranous pattern. 
 
 
 
 
 
 
X 60 
111 
 
 
 
 
 
 
Figure 5.28 Another example of FITC conjugated anti-IgG antibodies in a patient with 
COPD demonstrating mildly increased immunofluorescence on HUVEC in 
predominantly a membranous pattern. 
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Figure 5.29 Anti-IgM antibodies in an IPF patient demonstrating moderate 
immunofluorescence on HUVEC. 
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Figure 5.30 An example of moderate fluorescence in a patient with IPF following 
incubation with FITC conjugated anti-IgG antibody on endothelial cells. 
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Figure 5.31 Endothelial cells demonstrating a membranous pattern of staining 
following incubation with FITC conjugated anti-IgM antibody in a patient with 
idiopathic pulmonary fibrosis. 
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Figure 5.32 Anti-IgG antibodies in a control patient without ILD demonstrating 
minimal fluorescence on endothelial cells. 
 
 
Figure 5.33 HUVEC demonstrating minimal fluorescence following incubation with 
FITC conjugated anti-IgG antibodies in a patient with Sjogren’s associated ILD. 
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Anti-epithelial antibodies and pulmonary function 
As part of the evaluation of immune mediated injury, I examined the relationship of 
anti-epithelial antibodies with lung function impairment measured by percent 
predicted FVC and TLco.  The data showed that there was a significant negative 
correlation between IgG antibodies and percent predicted FVC (P=0.031; General 
linear model for correlation; Figure 5.34a) but not with carbon monoxide gas 
transfer TLco (P=0.653; Figure 5.34b).  Furthermore, there was no significant 
correlation between IgM antibodies and pulmonary function parameters (data not 
shown). 
 
Figure 5.34a The correlation between IgG antibodies against A549 cells and percent 
predicted FVC was significant. 
P=0.03 
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Figure 5.34b The correlation between IgG antibodies against A549 cells and percent 
predicted TLco was not significant. 
 
 
Anti-endothelial antibodies and pulmonary function 
In contrast to anti-epithelial antibodies, anti-endothelial antibodies did not have a 
significant correlation with parameters of lung function including percent predicted 
FVC and TLco (Table 5.7).   
 
 
 
P=0.65 
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Table 5.7 Anti-endothelial antibodies and lung function 
Antibody    Lung Function parameter                      P Value 
IgG   Vs  FVC      0.43 
IgG   Vs   TLco      0.29 
IgM   Vs  FVC      0.42 
IgM   Vs  TLco      0.88 
5.4 Discussion 
The conventional theory regarding the initial molecular mechanisms in IPF had 
focused on a predominant inflammatory model with subsequent fibrosis.  However, 
the lack of steroid responsiveness has argued against this model and the current 
understanding of IPF pathogenesis focuses upon abnormal wound healing response 
to an as yet unidentified insult(s).  An immunological mechanism of alveolar 
epithelial injury in response to multiple hits to pulmonary parenchyma followed by 
imbalance favouring T-helper type II immunity, failure of re-epithelialization and 
release of pro-fibrotic growth factors is plausible (Strieter 2005). 
In the present study, we have demonstrated a possible role of IgG antibodies 
against alveolar epithelial cells in the pathogenesis of IPF.  As alveolar epithelial 
injury is believed to be one of the earliest events in the fibrotic process in IPF, the 
finding of significantly increased immunofluorescence with anti-IgG antibodies in a 
membranous pattern supports this “epithelial hypothesis”.  Although the exact 
nature of this epithelial cell injury is unknown, there is evidence of a role of immune 
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mediated mechanisms culminating in a fibrotic response after lung injury in IPF 
(Ward 1979).  Furthermore, administration of immune complexes may induce 
pulmonary fibrosis in animal models (Bellon et al. 1982) and elevated levels of 
immune complexes have been demonstrated in bronchoalveolar lavage fluid (BALF) 
in IPF (Dall'Aglio et al. 1988;Dreisin et al. 1978;Haslam et al. 1979).   
Anti-epithelial cell antibodies have been described in the pathogenesis of IPF 
(Dobashi et al. 1999;Dobashi et al. 2000b;Dobashi et al. 2000a;Fujita et al. 1999a) 
and other interstitial lung diseases, such as radiation pneumonitis and pulmonary 
fibrosis associated with dermatomyositis (Fujita et al. 1999b).  Fujita and colleagues 
(Fujita et al. 2000;Fujita et al. 2004) evaluated cytokeratin-19 fragment and 
cytokeratin 8 and 18 in a series of patients with radiation pneumonitis.  There were 
significantly elevated levels of cytokeratin-19 antibody in patients with radiation 
pneumonitis with a significant correlation with disease progression.  Dobashi and 
colleagues (Dobashi et al. 2000a) evaluated antibodies to cytokeratin-18 in IPF and 
found significantly elevated levels of this antibody by Western blot.  Moreover, 
there was evidence of a significant increase in CK18: anti-CK 18 immune complexes 
in sera of IPF demonstrated by ELISA.  Together, these findings do support the role 
of immune mediated mechanisms in the pathogenesis of usual interstitial 
pneumonia (UIP), the histological counterpart of IPF; as well as in connective tissue 
disease associated pulmonary parenchymal injury. 
The findings of differential fluorescence and a significant relationship of IgG 
anti-epithelial antibodies with percent predicted forced vital capacity is thought 
provoking and the pathophysiological basis of this observation could be speculated.  
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It is possible that there is a linear relationship between epithelial cell injury and lung 
function impairment which has been demonstrated by this association.  However, 
failure of TLco being significantly correlated with antibodies to alveolar epithelial 
cells somewhat reduces the credibility of this hypothesis.  Indeed TLco may be too 
insensitive to show a significant association with epithelial damage as FVC is a 
reliable predictor of poor outcome in IPF (Zappala et al. 2010) and is probably more 
sensitive than TLco which is dependent on a number of other co-existing factors, 
such as emphysema.  
Antibodies to endothelial cells have been investigated in the pathogenesis of 
different autoimmune diseases.  Magro and co-workers (Magro et al. 2007) 
investigated 16 patients with connective tissue disease associated pulmonary 
fibrosis for immune mediated microvascular injury. Interestingly, there were 
significantly increased IgA anti-endothelial antibodies in patients with Rheumatoid 
arthritis.  Moreover, there was serologic and pathologic evidence of immune based 
microvascular injury in that cohort of patients.  Indeed, the microvascular injury has 
been demonstrated in the evolution of IPF by a study of 19 patients (Magro et al. 
2003) showing septal capillary injury along with immunofluorescent evidence of 
antibody mediated injury to pulmonary microvasculature.  Furthermore, circulating 
antiphospholipid antibodies were present in 18 patients tested for these antibodies.  
These data support the role of vascular injury in the pathogenesis of idiopathic 
pulmonary fibrosis.  Although our study failed to show a differential fluorescence 
with endothelial cells, a subset of patients did have some membranous 
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enhancement (Figures 5.29-5.31) and a larger study may be able to evaluate 
endothelial dysfunction at cellular level in greater detail. 
In conclusion, the findings of this study provide evidence in support of 
epithelial cell injury hypothesis in association with circulating IgG antibodies in IPF.  
As our understanding of IPF pathogenesis unfolds, it is becoming apparent that it is a 
disease of alveolar epithelial/endothelial interface and microvascular dysfunction 
secondary to immune dysregulation.  This aspect of the pathogenesis must be 
explored further to expand our knowledge of this devastating fibrotic disorder. 
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CHAPTER 6: CARCINOEMBRYONIC ANTIGEN AND IDIOPATHIC 
PULMONARY FIBROSIS 
6.1 Introduction 
Carcinoembryonic Antigen (CEA) is a glycoprotein involved in cell adhesion 
and is produced during foetal development.  The production of this antigen ceases 
soon after birth and a very small amount is detectable in normal healthy individuals.  
However, higher levels of CEA are present in smokers (Stevens & Mackay 1973) and 
this effect is pronounced in male smokers (Fukuda, Yamakado, & Kiyose 1998).  
There are several tumours associated with raised CEA level in serum such as 
colorectal, gastric, pancreatic, lung and breast carcinoma (Figure 6.1).  In addition, 
raised level of this tumour marker has also been found in non-malignant conditions 
such as ulcerative colitis, pancreatitis, cirrhosis and ascites.  The high level of CEA in 
lung malignancy reflects a marker of histological aberration in the lower respiratory 
tract and may be a hallmark of epithelial dysplasia and metaplasia.  Recently, 
squamous cell carcinoma antigen has been demonstrated to be expressed by 
metaplastic epithelium in IPF.  The primary aim of this study was to evaluate 
correlation between CEA concentration in serum and pulmonary function 
impairment as measured by percent predicted FVC and TLco.  Moreover, a lung 
biopsy specimen with UIP pattern associated with IPF and raised CEA level was 
stained to explore the probable source of CEA rise in IPF. 
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Figure 6.1 The suspected pathopysiology of carcinoembryonic antigen production 
and release from malignant tumours and mucosal lining of gastrointestinal and 
respiratory tract. The speculated mechanism of elevated CEA level in pulmonary 
fibrosis is the release of this molecule from metaplastic respiratory epithelium. 
 
Epitheilal tumour markers and Pulmonary Fibrosis 
There is increased incidence of lung cancer reported in patients with 
pulmonary fibrosis of uncertain aetiology (Fraire & Greenberg 1973;Haddad & 
Massaro 1968;Turner-Warwick et al. 1980).  Moreover, there is evidence of raised 
CEA level in BALF of IPF patients (Takahashi et al. 1985).  The exact mechanism for 
raised serum level of this antigen in IPF is not known.  However, atypical epithelial 
proliferation and squamous metaplasia seen in lung biopsy specimens of patients 
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with idiopathic interstitial fibrosis (Haddad & Massaro 1968) may be one of the 
mechanisms responsible for CEA elevation in IPF.  The prevalence of raised CEA level 
in heavy smokers is 13.6% as compared to 1.8% in non smokers (Stevens & Mackay 
1973).  The rise of CEA in heavy smokers may reflect a marker of dysplasia and or 
metaplasia of respiratory epithelium secondary to cigarette smoke.   
There is evidence of significantly raised levels of carbohydrate antigen CA15-
3 in UIP/IPF and advanced sarcoidosis (Ricci et al. 2009).  This rise in CA 15-3 does 
have a significant correlation with decreased diffusion capacity and worsening 
fibrosis scores on HRCT scan.  This finding of a close association of tumour markers 
with interstitial pulmonary fibrosis was the rationale to investigate this interesting 
association in further detail. 
In this study, we measured the serum level of CEA in a cohort of IPF patients 
and evaluated any possible correlations between CEA level with lung function 
impairment, measured by forced vital capacity (FVC) and carbon monoxide diffusion 
capacity (TLco) and fibrosis scores on HRCT scan.  Furthermore, the subjects were 
sub-categorized into two groups on the basis of total gas transfer impairment 
threshold of 40% as it is indicative of severe disease in IPF (Bradley et al. 2008).  A 
subgroup analysis was undertaken to evaluate any significant difference in CEA level 
between these two groups. 
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6.2 Statistical analysis  
The data were analysed by SPSS (Version 17, Chicago, IL).  The correlations between 
serum CEA, lung function parameters and fibrosis extent were evaluated by Pearson 
correlation.  An α-value of 0.05 was considered statistically significant. 
6.3 Results 
The main demographics and clinical characteristics of the study population are 
shown in Table 6.1.  Two patients were excluded in view of the diagnoses of rectal 
adenocarcinoma and pancreatic carcinoma. 
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Table 6.1 
Selected demographics of study participants 
                   IPF (ATS/ERS criteria)    
      
Subjects (n)                                 43 
Excluded (n)                2 
Age (years, meanSD)               737.1                                                                        
Gender  
Male (n)                     29 
Female (n)                       12 
Smoking (n) 
Ex                       39 
Never                 2 
Current                 0 
FVC (L)                                              3.00.9 
FVC (% predicted)                     8820 
TLco (% predicted)                  5219 
Fibrosis score on HRCT  (n, %) 
Minimal (0-25%)                25 (61%) 
Moderate (26-50%)     8 (19%) 
Severe (51-75%)     6 (15%) 
End stage (76-100%)       2 (5%) 
Pattern of fibrosis (n, %) 
Reticular      9 (22%) 
Honeycombing                 10 (24%) 
Mixed                     22 (54%) 
Data are presented as meanSD or percentage % unless stated otherwise 
FVC: forced vital capacity; TLco: Total gas transfer for carbon monoxide.  
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The mean CEA level (±SD) in the study cohort was 5.9±4.7 (ng/ml) (Figure 6.2).  
Normal range for CEA is 0-5 ng/ml. 
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Figure 6.2 Serum CEA concentrations (ng/ml) in the study cohort of IPF patients. 
Bar = median. 
 
Carcinoembryonic antigen in relation to gas exchange  
To evaluate CEA level in relation to the degree of pulmonary gas exchange 
abnormality, the study group was divided into two categories with respect to 
impairment of gas exchange (TLco) for carbon monoxide at a threshold of <40% of 
predicted and ≥40%.  The data show that CEA level was significantly raised in the 
group with worse gas exchange abnormality (Figure 6.3).  
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Figure 6.3 Comparison of serum CEA concentration in IPF patients with TLco ≤ 40% 
predicted (severe disease) and TLco > 40% predicted. CEA is significantly higher in the 
severe disease group (p=0.006) 
 
There was evidence of a significant correlation between CEA and percent 
predicted FVC (Figure 6.4; R2=0.19, P<0.01) as well as TLco (Figure 6.5; R2=0.20, 
P<0.01).  Furthermore, there was a significant correlation between CEA level and 
corrected gas transfer coefficient of carbon monoxide, Kco (P=0.029; data not 
shown). 
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Figure 6.4 The correlation between serum CEA concentrations and percent predicted 
FVC (P=0.005) 
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Figure 6.5 The correlation between serum CEA concentrations and percent predicted 
TLco (P=0.006) 
 
HRCT fibrosis scores and CEA level 
The extent of fibrosis correlated significantly with carcinoembryonic antigen 
concentration (P=0.027; Pearson correlation; Figure 6.6).  However, the pattern of 
fibrosis did no correlate significantly with CEA level (P=0.946; data not shown).   
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Figure 6.6 The serum concentrations of CEA in relation to the extent of fibrosis on 
HRCT scan. The four categories refer to worsening interstitial pulmonary fibrosis 
where 1=minimal fibrosis and 4=advanced fibrosis affecting 76-100% of lung 
parenchyma. 
 
Similar to pulmonary function parameters, the association of CEA with 
pulmonary fibrosis extent was weak and a larger sample size might be able to clarify 
the link between rising CEA and lung fibrosis more accurately.  The association of 
lung fibrosis severity with raised CEA level provides a further evidence of abnormal 
epithelial proliferation at pulmonary micro-alveolar level with the release of 
carcinoembryonic antigen. 
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Immunohistochemistry  
As shown in Figure 6.7, there is evidence of a strong CEA staining of 
metaplastic epithelium lining the honeycomb cysts as well as respiratory 
bronchioles.  Furthermore, there is no significant staining observed in normal lung 
tissue. A lung biopsy specimen from a patient who had undergone lobectomy was 
used as a control. There was no evidence of significant CEA staining observed in 
control biopsy specimen (Figure 6.8). 
 
 
Figure 6.7a Expression of carcinoembryonic antigen in lung biopsy specimen in 
epithelial lining of respiratory bronchioles (arrows) in a patient with IPF. 
(Photomicrograph provided by Dr A. Campbell)  
0.2mm  
X 250 
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Figure 6.7b There is strong staining of metaplastic epithelial cells lining the 
honeycomb cysts (dark brown colour; white arrows). The more diffuse light brown 
non specific staining is likely to be secondary to mucus (black arrows). 
(Photomicrograph provided by Dr A. Campbell) 
 
 
 
X 250 
0.2mm  
134 
 
 
 
 
 
 
 
Figure 6.8 The control lung biopsy specimen from a patient undergone lobectomy. 
There is no significant CEA staining of bronchiolar epithelium in this tissue section. 
(Photomicrograph provided by Dr A. Campbell) 
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6.4 Discussion 
This prospective study of evaluation of carcinoembryonic antigen in 
idiopathic pulmonary fibrosis suggests that there is evidence of high serum level of 
this tumour marker in peripheral blood of patients with pulmonary fibrosis.  
Moreover, the raised CEA level has a significant correlation with lung function 
impairment, measured by forced vital capacity and carbon monoxide gas transfer.   
Our findings are in accordance with a retrospective study of patients 
undergoing lung transplantation.  Hadjiliadis and colleagues (Hadjiliadis et al. 2001) 
evaluated the prognostic significance of serum CEA in 200 patients who underwent 
lung or heart-lung transplant at a University Hospital.  The IPF group had the highest 
pre-transplant CEA level among the other indications for lung or heart-lung 
transplantation.  However, rising CEA levels were unable to predict post-transplant 
survival. 
The association of abnormal epithelial proliferation with idiopathic 
interstitial fibrosis has been recognized for more than 40 years.  Haddad and 
Massaro (Haddad & Massaro 1968) evaluated 8 cases of diffuse idiopathic 
pulmonary fibrosis and found evidence of squamous metaplasia, epithelial 
stratification and atypical proliferation in the majority.  It is plausible that the 
cuboidal epithelium lining the honeycomb areas observed in IPF may be the source 
of this antigen release into the respiratory secretions and subsequent elevation in 
the serum of these patients with pulmonary fibrosis.  Abnormal re-epithelilalization 
plays a role in the pathogenesis of IPF as suggested by the presence of 
bronchiolization and the presence of abnormal proliferation of epithelial cells at 
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bronchiole-alveolar junction (Chilosi et al. 2002).  Furthermore, there is evidence of 
an association between terminal bronchiolar carcinoma and interstitial pulmonary 
fibrosis (Spain 1957).   
The close association of respiratory epithelial damage with the release of 
CEA in IPF is strengthened by a study of BALF and serum measurement of CEA in 26 
patients with histologically confirmed IPF (Takahashi et al. 1985).  The ratio of 
carcinoembryonic antigen to albumin (CEA/Alb, ng/mg) was measured in BALF in 
patients with IPF, smoking control subjects, sarcoidosis, hypersensitivity 
pneumonitis and lung cancer.  The serum CEA was significantly higher in IPF group 
with or without lung carcinoma.  CEA/Alb ratio was high in smoking controls, IPF and 
primary lung cancer than other interstitial lung diseases.  Moreover, CEA/Alb ratio of 
BALF was significantly higher than serum, suggesting that majority of CEA in BALF is 
derived from pulmonary parenchyma.  However, there was no correlation between 
BALF CEA/Alb ratio and serum CEA values.   
IPF is associated with interstitial inflammation and structural remodelling of 
pulmonary interstitium.  During the process of fibrosis, epithelial cells undergo a 
range of morphological changes from large cells to cuboidal, columnar or squamous 
cells (Carrington et al. 1978), cytoskeletal changes, loss or expression of adhesion 
molecules and formation of transitional phenotypes between type II and type I cells 
with limited regenerative capacity (Kasper & Haroske 1996).  Moreover, there is 
diversity of molecular expression of pneumocytes during the proliferation and 
metaplastic changes in the process of interstitial fibrosis (Fujita et al. 1999a;Lappi-
Blanco et al. 2006;Papadopoulos et al. 1993;Ricci et al. 2009).  Dobashi and 
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colleagues (Dobashi et al. 1999) showed that proliferating type II pneumocytes 
express anti-human cytokeratin 19 antibodies in interstitial fibrosis.  Moreover, 
intense staining of carbohydrate antigen CA 15-3 has been demonstrated in 
fibroblasts within the fibroblastic foci and cell cultures of lung fibroblasts from IPF 
lungs (Ricci et al.  2009).  However, CEA expression by alveolar epithelium in IPF 
lungs has not been described in the literature. 
This study demonstrates that the metaplastic epithelium lining the 
honeycomb areas is the likely source of CEA release into the respiratory secretions.  
Immunohistochemical analysis of lung tissue with UIP pattern and significantly 
elevated serum CEA has clearly delineated a strong CEA staining with no significant 
uptake of this antigen by normal lung tissue.  As cuboidal pneumocytes are the 
predominant source of epithelial renewal in severe lung damage and fibrosis 
(Kawanami, Ferrans, & Crystal 1982), these cells are an attractive source of CEA 
release in IPF/UIP.  To our knowledge, it is the first demonstration of CEA positivity 
in honeycombed bronchioles in IPF and provides the evidence of a novel mechanism 
of CEA rise in BALF and subsequently in the peripheral circulation.   
Limitations of the study 
It is important to acknowledge the fact that although the correlation 
between CEA level and pulmonary function is statistically significant, it is a weak 
correlation and a larger sample size might be able to evaluate this association in 
greater detail.  Secondly, the fibrosis scores to correlate with CEA level were done by 
a single observer.  The scoring of lung fibrosis by multiple observers would have 
increased the credibility of the observed association between carcinoembryonic 
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antigen and interstitial pulmonary fibrosis.  Finally, the measurement of CEA was 
carried out once for each patient and it will be interesting to evaluate the 
association of CEA with lung function decline with repeated measurements of this 
serum tumour antigen parallel to pulmonary function assessment. 
In conclusion, this study has demonstrated a negative correlation between 
serum elevation of carcinoembryonic antigen and pulmonary function in idiopathic 
pulmonary fibrosis.  These findings do provide us with further insight into the 
pathophysiology of gas exchange abnormality and epithelial aberration in this 
restrictive lung disease of poor prognosis.  On the basis of significant negative 
correlation between lung function impairment and CEA, it may be a potentially 
useful biomarker during the course of IPF and may be utilized as an additional guide 
to commence therapy in patients with progressively worsening pulmonary function.  
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CHAPTER 7: CONCLUDING REMARKS  
The spectrum of alveolar injury in IPF is protean and different aspects of alveolar 
epithelial and endothelial involvement were evaluated during this work.  The 
association of vascular derangement in form of platelet-monocyte aggregates was 
investigated in a flow cytometry based analysis.  Platelet-monocyte adhesion was 
found to be significantly increased in IPF and this aggregation was independent of 
cardiovascular risk factors in the IPF population.  Although this thesis did not explore 
the detailed molecular mechanisms of this binding, it has provided supportive data 
for a vascular injury hypothesis in line with similar observations in cardiovascular 
diseases.  The findings of this study provide corroborative evidence of the role of 
platelets in this fibrotic disease with a strong association with vascular disease. 
The immune mediated ‘epithelial hypothesis’ investigation revealed that IgG 
antibodies are likely to be involved in the pathogenesis of alveolar epithelial injury.  
These IgG antibodies had a significant correlation with declining lung function 
measured by FVC, supporting the pathogenic role of the immune mediated 
mechanisms responsible for epithelial injury and pulmonary fibrosis.  Moreover, 
respiratory epithelial disruption at the level of respiratory bronchioles and 
honeycomb cysts could be the mechanism responsible for carcinoembryonic antigen 
rise and an association of the elevated CEA and lung function impairment was 
demonstrated in IPF.  The significant correlation of fibrosis scores with CEA rise 
substantiates the evidence of close relationship of epithelial aberration and lung 
fibrosis in IPF.   
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The role of gastro-esophageal reflux in the pathogenesis of IPF has been 
debated for a long time.  An association of reflux with IPF was confirmed on 
subjective assessment of symptom based questionnaire addressing both acid and 
non-acid reflux and it is likely that non-acid reflux might play a significant role in 
perpetuating the aspiration related alveolar epithelial injury.  The novel techniques 
for the assessment of this type of reflux would provide further insight into the 
pathophysiology of reflux induced pulmonary parenchymal injury.  It will be of 
crucial importance to evaluate reflux by means of upper airway pH analysis and 
repeated measurement of exhaled breath markers of gastro and extra-esophageal 
reflux such as pepsin and bile salts. 
This thesis has substantiated the evidence of the role of immune mediated 
mechanisms in the pathogenesis of IPF.  Platelets in conjugation with monocytes are 
a potential source of endothelial injury and pro-thrombotic state and further studies 
evaluating clotting factors and Von Willebrand Factor in relation to platelet 
activation may provide us with further insight into the pathophysiology of IPF at 
microscopic and cellular level. Furthermore, it will be important to study the effects 
of platelet agonists such as adenine di-phosphate and thrombin on platelet-
monocyte adhesion. 
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